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!BSTRACTÖ
Actinobacillus pleuropneumoniae is a major cause of respiratory disease in pigs, causing 
animal suffering and substantial economic losses. The aim of this thesis was to obtain 
more knowledge on the protective immunity to infections with A. pleuropneumoniae 
and to evaluate potential strategies in preventing and combating A. pleuropneumoniae 
infections. 
Investigations regarding the role of maternal immunity for the protection of the 
offspring and the subsequent effect on the epidemiology on herd level demonstrated 
that the levels of serum antibodies to A. pleuropneumoniae in sows were reflected in 
colostral levels. The colostral levels were in turn reflected in the levels of serum 
antibodies in the offspring and piglets with high levels of antibodies also had 
detectable levels of antibodies for a longer time compared to the offspring to sows 
with low levels of antibodies to A. pleuropneumoniae. 
An inoculation of naïve pigs with A. pleuropneumoniae induced acute-phase 
protein responses. The response to the inoculation was clearly affected by the 
antimicrobial treatment administered at the onset of clinical signs of respiratory 
disease. The response of these pigs to a second inoculation was also influenced by 
the treatments carried out after the first inoculation. Enrofloxacin was superior in 
reducing clinical signs but left pigs unprotected at the second inoculation. 
Tetracycline demonstrated a similar treatment efficacy as enrofloxacin but pigs were 
protected at challenge as were the penicillin treated pigs. Penicillin was on the other 
hand not efficient in curing diseased pigs. The pigs that were protected from disease 
at the second inoculation had all developed serum antibodies to A. pleuropneumoniae 
following the first inoculation and an acute-phase response was not induced 
following the second inoculation. The results therefore indicate that antibodies 
mirror protection against disease well. 
Vaccinations against actinobacillosis in a fattening herd did not provide 
protection against clinical disease. However, in combination with intensified 
treatments of pigs with signs of respiratory disease, pleurisy registrations at slaughter 
decreased over time although the growth rate was unaffected.  
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To all four-legged friends that have crossed my path 
 
The seemingly impossible is possible 
Hans Rosling  
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!BBREVIATIONSÖ
AI Artificial  insemination 
Apx  Actinobacillus pleuropneumoniae RTX-toxin 
BALF  Bronchoalveolar lavage fluid 
BALT  Bronchus associated lymphoid tissue 
CPS Capsular  polysaccharide 
DWG  Daily weight gain 
ELISA  Enzyme linked immunosorbent assay 
Ig Immunoglobulin 
IL Interleukin 
LPS Lipopolysaccharide 
MIC  Minimal inhibitory concentration 
NAD  Nicotinamide adenine dinucleotide 
NVI  National Veterinary Institute (SVA) 
OMP  Outer membrane protein 
PBS-T  Phosphate-buffered saline with Tween  
PCR  Polymerase chain reaction 
PCV2  Porcine circovirus type 2 
PFGE  Pulsed-field gel electrophoresis 
Pig-MAP  Pig Major acute-phase protein 
pMBL  Porcine mannan-binding lectin 
PRDC  Porcine respiratory disease complex 
PRRSV  Porcine reproductive and respiratory  
RTX  Repeats in the structural toxin 
SAA  Serum amyloid A 
SJV  Jordbruksverket/Swedish Board of Agriculture 
SPF  Specific pathogen free 
SVA  Statens veterinärmedicinska anstalt 
TNF  Tumor necrosis factor   9 
 "ACKGROUNDÖ
As many diseases affecting pigs are dependent on the production system in 
which pigs are reared, a brief description of the development and the present 
structure of pig production in Sweden is given below. The major respiratory 
pathogens will also be briefly mentioned to provide a background for this 
thesis. As the immune system plays an important role in the pathogenesis of 
actinobacillosis, a brief introduction to the immune parameters mobilized in 
the respiratory tract of pigs infected with Actinobacillus pleuropneumoniae is 
given as well. 
 0IGÖPRODUCTIONÖINÖ3WEDENÖ
 4HEÖ3WEDISHÖPIGÖPOPULATIONÖ
Pig production has changed considerably over the years ever since 
domestication took place. The most dramatic changes have occurred during 
the last 200 years. This time period coincides with the industrial revolution 
when also the human population increased which in turn led to an increase 
in the demand for food.  
 
The number of pigs in Sweden during the major part of the nineteenth 
century remained relatively constant at approximately 500 000. The pig 
population only began to increase during the last decade of the 1800’s. After 
this, the number of pigs varied during the first half of the 1900’s but then 
steadily increased until the 1980’s. From 1985 when there were 2 645 797 
pigs in Sweden, the highest number recorded, the number of pigs have 
declined with 44% to 1.5 million pigs in 2009 (SJV, 2010b). 
   10 
A reduction has also been seen in the number of pig herds which has 
decreased with 90% from 26 122 in 1980 to only 2 380 in 2008. As the 
number of herds has decreased more than the number of pigs, the average 
herd size has consequently increased. In 1980, piglet producing herds on 
average had 15 sows (including boars) while this number had increased to 80 
in 2009. The same pattern holds true for fattening herds which on average 
had 81 fattening places per herd in 1980. In 2009, this figure was 532 places 
per herd (SJV, 2010b). Two thirds of the total number of sows belonged to 
herds with 200 or more sows which only accounted for 15% or the total 
number of piglet producing herds.  
 3WEDISHÖANIMALÖWELFAREÖLAWÖREQUIREMENTSÖ
According to the Swedish animal welfare law, the area requirement is 0.17 
m
2 + (weight in kg/130 kg) m
2 for growing pigs (SJV, 2010a), which 
corresponds to an area of 0.4 m
2 per weaner of 30 kg and 0.94 m
2 for a 
market weight pig of 100 kg. Fully slatted floors are not allowed but about 
30% of the pen may have slats. 
 
Also all sows must be kept loose during all times. Normally, they are kept in 
groups during pregnancy and in individual pens during lactation. The use of 
farrowing crates is prohibited by law but individuals may be confined in 
crates for up to one week at parturition and insemination under special 
circumstances. The animal welfare law also prohibits weaning before four 
weeks of age, and weaning generally takes place at the age of four to five 
weeks.  
 4HEÖ3WEDISHÖBREEDINGÖSYSTEMÖ
The Swedish pig production is organized in the form of a pyramid with the 
nucleus herds (n=26) at the top, multiplying herds (n=42) second to the top, 
then piglet producing herds and fattening herds at the base (Figure 1). Piglet 
producing herds may also rear piglets to market weight in farrow-to-finish 
systems. In the piglet producing herds, Landrace (L) x Yorkshire (Y) sows, 
mated with either Duroc (D) or Hampshire (H) boars; give birth to three-
breed crosses for the production of slaughter pigs (H-YL or D-YL).   11 
Nucleus herds (26) 
Multiplying herds (42) 
Piglet producing herds 
Fattening herds 
 
Figure 1. The breeding structure of Swedish pig production. Arrows indicate movements of 
animals. (Number of herds) 
Traditionally, hybrid gilts (LY) have been sold from nucleus and multiplying 
herds to piglet producers, either as prospective gilts at a weight of 30 kg, as 
unmated gilts at an age of six months or as pregnant gilts at an age of 9-10 
months. The piglet producers replace on average 30-40% of their breeding 
stock annually. Artificial insemination (AI) is used for the vast majority 
(>95%) of the matings; and most boars are today only used for teasing. AI 
has made it possible for piglet producers to recruit their own breeding stock 
by using two-breed rotational crossing (Y x LY; L x YLY; Y x LYLY et. c.). 
An increasing number of herds have commenced to do so during the last 
decade, either for biosecurity or of economical reasons (or both). 
 0RODUCTIONÖSTRATEGIESÖ
Previously, most piglets were sold from specialized piglet-producing herds to 
specialized fattening-herds at an approximate age of 10 to 14 weeks when 
weighing 25 kg. Up to the 1980’s, there could be as many as 50 suppliers to 
one batch of approximately 400 fattening pigs. Today, growers weigh 
approximately 30 kg at the time of allocation to the fattening herd and they 
are usually between the age of nine to 12 weeks. Due to the increased herd 
sizes, specialized fattening herds of today usually contract two to four piglet 
producers in order to reduce the number of infection routes when 
establishing their batches. However, farrow-to-finish production systems; 
either within a herd, or in cooperation between herds, form an increasing 
part of the Swedish pig production. Further, today about 25% of the 
Swedish pig production takes place in fairly large (350 to 5000 sows) multi-
site-systems (sow-pool-systems). 
 (EALTHÖSTATUSÖOFÖ3WEDISHÖPIGSÖ
Sweden is located on the Scandinavian Peninsula, and together with a 
restricted import of live animals, the pig population has been quite isolated. 
Thus, the Swedish pig population has a favorable health status. Sweden is   12 
free from all diseases listed by the Office International des Epizooties (OIE), 
including Aujeszky’s disease (AD) and porcine reproductive and respiratory 
syndrome (PRRS), as well as from porcine epidemic diarrhea (PED) and 
transmissible gastro-enteritis (TGE). Aujeszky’s Disease was diagnosed in 
1963 and eradicated from Sweden in 1996 (NVI, 2010). Isolation of 
Salmonella spp. is rare, and since 1984 generally diagnosed in less than 5 pig 
herds per year (NVI, 2010). The few salmonella positive pigs are usually 
detected at slaughter and salmonella is not regarded as a clinical disease in 
pigs in Sweden. 
 
Nucleus and multiplying herds in Sweden are affiliated to extended control 
programs and are declared free from atrophic rhinitis (toxin producing 
strains of Pasteurella multocida), Salmonella spp, swine dysentery (Brachyspira 
hyodysenteriae) and mange (Sarcoptes scabei) in addition to the above listed 
diseases. 
 
In specific-pathogen free (SPF) systems, pigs are declared free from a 
number of defined microorganisms (Young, 1955). Pigs in the Swedish SPF 
system are apart from the infections mentioned above declared free from a 
number of major causes of respiratory infections such as PRRS-virus, 
Mycoplasma hyopneumoniae, toxin-producing P. multocida, A. pleuropneumoniae 
and swine influenza virus. The Swedish SPF system was introduced in 1988 
(Wallgren & Vallgårda, 1993a), and today about 4% of the Swedish sows 
belong to SPF production. Production parameters such as weight gain and 
feed conversion ratio are greatly improved in SPF-pigs (Wallgren et al., 
1993b). 
 
The organic pig production constitutes less than 1% of the total pig 
production in Sweden (Wallenbeck, 2009). There are no specific health 
qualifications for organic pig production, but the weaning age is higher 
(seven weeks) and the area requirements larger than for conventional pigs. 
 
So called growth-promotors (low dose antibiotics in feed), were introduced 
in the 1970’s, which improved production considerably, especially during 
the post weaning period. As the first country in the world, Sweden banned 
the use of growth promotors in 1986. During the subsequent years intestinal 
health problems of recently weaned piglets increased (Robertsson & 
Lundeheim, 1994), which necessitated improvements in the rearing systems 
in Swedish herds. Consequently, over 90% of the Swedish pigs are today   13 
reared in batch systems based on age-segregation from birth-to-slaughter 
(Holmgren, 2002). 
 
The most common diseases among pigs in Sweden are intestinal disorders in 
young growers and respiratory diseases in fattening pigs. In this context, it 
has been demonstrated that the likelihood of infection with respiratory 
diseases increased with increasing herd size (Moorkamp et al., 2009; Maes et 
al., 2000). Infections with M.  hyopneumoniae and A.  pleuropneumoniae are 
widespread in the conventional pig population in Sweden, but the influence 
of these diseases has decreased since the early 1990’s (Holmgren & 
Lundeheim, 2002). However, during recent years problems with A. 
pleuropneumoniae have increased again (Beskow et al., 2008). 
 $ISEASEÖPREVENTINGÖMEASURESÖ
After the ban of the use of growth-promoters in 1986, disease prevalence 
increased and consequently the use of therapeutic antimicrobials also 
increased (Wallgren, 2009). This forced farmers, veterinarians and scientists 
to seek alternative solutions and improve the rearing conditions in order to 
improve health status. The introduction of all in-all out procedures on a 
large scale reduced the incidence of recordings of respiratory lesions at 
slaughter at a national level (Holmgren et al., 1999), and today a majority of 
the pigs are reared in age-segregated rearing systems all the way from birth 
to slaughter. An improvement of the respiratory health status by 
implementation of all in – all out rearing has also been recorded elsewhere 
(Busch & Jensen, 2006; Cleveland-Nielsen et al., 2002). 
 
Other bio-security measures include restrictions for visitors, supplying 
visitors with protective clothes and boots, quarantine for purchased animals 
and refraining from introducing new pigs to the herd. Prevention of disease 
also includes attempts to eradicate specific pathogens, of which establishing 
SPF herds is the ultimate solution. 
 
Vaccination programs have also been widely employed against common 
infections. In general, all sows are vaccinated against neonatal colibacillosis, 
parvovirus and erysipelas. Some sows are vaccinated against porcine 
circovirus type 2 (PCV2). Growing pigs may be vaccinated against PCV2, 
M. hyopneumoniae and Lawsonia intracellularis.   14 
 0RODUCTIONÖPERFORMANCEÖÖ
As seen in Table 1, the productivity of the Swedish pigs varies between 
herds. Data on production performance is based on the data system for pig 
production, PigWin 2009. Based on the recordings from 72 000 sows in 186 
herds, sows in mean gave birth to 12.3 piglets per litter of which 10.5 were 
weaned, which corresponds to a yearly production of 23.0 piglets per sow 
per year. 
 
In 2009, pigs in Sweden reached market weight of 110 kg at 181 days of age 
while SPF pigs reach market weight at the age of 141 days. Conventional 
pigs required 35.4 MJ per kilo weight gain in mean while the 25% best 
performing herds only require 33.8 MJ. The mean daily weight gain 
(DWG) was 876 grams per day based on the recordings from 338 500 
slaughtered pigs from 120 herds.  
 
The mortality of piglets from birth to weaning was 17.0% and with a 
mortality of 2.3% during the weaning period. The mortality during the 
fattening period was 2.4% on average and 1.8% for the top 25% herds. 
Table 1. Swedish pig production performance in 2009 according to PigWin.  
Production parameters sows  SPF  Top 25%  Mean  Bottom 25% 
Weaned piglets per sow and year  25.2  25.4  23.0  19.0 
Live-born piglets per litter  13.5  13.7  12.3  10.4 
Weaned piglets per litter  11.5  11.6  10.5  8.6 
Mortality from birth to weaning (%)  15.5  14.8  17.0  20.7 
Mortality from weaning to delivery (%)  0.1  1.6  2.3  3.6 
Age at 30 kg bw (days)  70  80  83  86 
Production parameters fatteners         
Daily weight gain from 30 kg bw (g/day)  1024  909  876  845 
Age at slaughter (days)  141  171  181  192 
Feed conversion (MJ/kg bw)  -  33.8  35.4  37.4 
Mortality from delivery to slaughter (%)  0.5  1.8  2.4  3.2 
 
 2EGISTRATIONSÖATÖSLAUGHTERÖ
Recordings made in the routine meat inspection at slaughter can be a 
valuable tool when evaluating the health status of pig herds over time. 
However, the lung lesions observed at slaughter do not provide information 
on the specific etiological causes of the lesions (Jirawattanapong et al., 2009).   15 
 0ORCINEÖRESPIRATORYÖDISEASEÖCOMPLEXÖÖ
Porcine respiratory disease complex (PRDC) is a multifactorial disease 
syndrome involving several respiratory pathogens. Commonly isolated 
bacterial pathogens are A. pleuropneumoniae, M. hyopneumoniae, P. multocida, 
Streptococcus suis and Haemophilus parasuis and  common viral pathogens 
include porcine reproductive and respiratory syndrome virus (PRRSV), 
swine influenza virus (SIV), PCV2 and porcine respiratory coronavirus 
(Thacker, 2001). The most frequently isolated pathogens differ between 
countries (Hansen et al., 2010; Kim et al., 2003; Thacker, 2001). From an 
international perspective, PRRSV is one of the major pathogens (Thacker, 
2001). Sweden was free from PRRS until 2007 when a total of seven 
production sites were infected with the European strain of the virus. These 
sites were stamped out and the country was again declared free from PRRS 
in the same year (Carlsson et al., 2009). However, Sweden is currently 
experiencing emerging problems with A. pleuropneumoniae (Beskow et al., 
2008).  
 
Finishing pigs between the age of 14 and 20 weeks are most commonly 
affected by PRCD (Thacker, 2001), but there are large variations in 
morbidities and mortalities between herds (Sørensen, 2006). PRDC is 
characterized by growth retardation; reduced feed-conversion efficiency, 
anorexia, fever, cough and dyspnoea. Lesions are mainly found in the 
anterio-cranial parts of the lungs and there is usually fibrotic pleurisy of the 
diaphragmatic lobes. The lesions are of course dependent on the pathogens 
involved.  
 -AJORÖBACTERIALÖPATHOGENSÖASSOCIATEDÖWITHÖ02$#Ö
M. hyopneumoniae is a major cause of respiratory disease in pigs, most often 
occurring as subclinical infections in growing and finishing pigs, causing 
growth retardation (Rautiainen et al., 2000; Wallgren et al., 1993). M. 
hyopneumoniae infections are considered to be endemic in most herds and as 
many as 90% of the pigs have seroconverted at the time of slaughter (Maes et 
al., 2000; Maes et al., 1999; Wallgren et al., 1993). Transmission of M. 
hyopneumoniae by carrier pigs is considered to be the main source of 
infection under field conditions as infected pigs may harbour the microbe in 
the respiratory tract for up to 200 days (Pieters et al., 2009). M. 
hyopneumoniae colonizes the airways by binding to cilia of epithelial cells in 
the respiratory tract. This results in a reduced capacity of the mucociliary 
apparatus to clear the respiratory tract of debris and microorganisms which   16 
in turn paves the way for other respiratory pathogens such as P. multocida 
and Bordetella bronchiseptica.  
 
Pasteurella multocida, a Gram-negative facultative anaerobic bacteria, is 
commonly isolated from the nasal cavity of pigs, including SPF pigs, and 
pneumonic pasteurellos is often considered as the common final stage of 
PRDC (Pijoan, 2006). There are five serogroups of P. multocida strains (A, 
B, D, E and F), classified according to their capsule antigens. Strains 
associated with pneumonia are rarely toxin-producing and most often they 
belong to serogroup A, but they may also be type D which is toxin-
producing and causes atrophic rhinitis in growing pigs. P. multocida is often 
isolated from pigs primarily infected with M. hyopneumoniae. The chronic 
form of  disease is most common in which occasional coughing and 
sometimes a slight rise in temperature is observed (Bölske et al., 1980). The 
clinical signs are thus indistinguishable from those associated with M. 
hyopneumoniae. Varying degrees of pleuritis is also associated to P. multocida 
infections which make the lesions indistinguishable from those caused by A. 
pleuropneumoniae  as seen at the post-mortem inspection at slaughter 
(Jirawattanapong et al., 2009). 
 -AJORÖVIRALÖPATHOGENSÖASSOCIATEDÖWITHÖ02$#Ö
The two major viral infections included in the PRDC complex are SIV and 
PRRSV. SIV readily undergo changes in their hemagglutinin (H) and 
neuraminidase (N) glycoproteins causing new variants of differing virulence 
to arise. Infections with SIV in naïve pig herds usually cause a sudden onset 
of disease symptoms in a large number of animals displaying symptoms such 
as anorexia, lethargy and fever. Acute outbreaks of SIV are clinically 
indistinguishable from those of acute actinobacillosis (Tobias et al., 2009). 
Infections with SIV have attracted more attention following the 2009 
pandemic HINI-influenza among humans which was also transmitted to pigs 
with non-existing to mild or moderate disease symptoms (Hofshagen et al., 
2009). 
 
PRRSV has become a major pathogen of most swine producing countries 
over the last decades. Apart from causing reproductive failure including 
abortions, it is also a major cause of respiratory disease in growers and 
fatteners. Symptoms vary depending on the route of infection and the virus 
strain. Concurrent infections also affect the course of disease (Hansen et al., 
2010). 
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A third virus included in the PRDC complex is PCV2. PCV2 is involved in 
post-weaning multisystemic wasting syndrome in growing pigs. The most 
prominent symptom is wasting which cause pigs to rapidly lose weight and 
body condition, but also an interstitial pneumonia is commonly seen 
histopathologically in affected pigs. 
 0ARASITICÖPATHOGENSÖASSOCIATEDÖWITHÖ02$#Ö
A number of parasites may also be involved in the PRDC complex. The 
most common gastrointestinal parasite in pigs, Ascaris suum, may cause 
respiratory disease symptoms such as coughing and difficulty in breathing as 
larvae migrate from the intestine to the liver and then to the lung before 
being swallowed to finally mature in the gut. The damage to the lungs 
caused by the migrating larvae may pave the way for secondary bacterial 
invasions (Stewart, 2006). 
 
Also lung worms (Metastrongylus  spp.) causes lung damage under larval 
migration. This may induce coughing in itself, but may also facilitate 
subsequent infections preferably caused by common bacterial infections, 
such as M. hyopneumoniae,  A. pleuropneumoniae, P.  multocida and S.  suis 
(Stewart, 2006). 
 !CTINOBACILLUSÖPLEUROPNEUMONIAEÖ
A. pleuropneumoniae belongs to the family Pasteurellaceae  (VetBact, 2010; 
Brenner, 2005), and is known to cause disease in a number of species 
including humans. In bovines, Actinobacillus lignieresii is the cause of 
actinomycosis (wooden tongue) which was first accounted for in 1902 from 
subcutaneous abscesses in the head and neck region of Argentinean cattle 
(Rycroft & Garside, 2000). In humans, Actinobacillus actinomycetemcomitans 
causes periodontal disease (Henderson et al., 2002) and in horses 
Actinobacillus equuli is the cause of fatal septicaemia in foals (Sternberg, 1999).  
 
A. pleuropneumoniae, formerly Haemophilus pleuropneumoniae, H. 
parahaemolyticus,  is a small to medium-sized, haemolytic, facultative 
anaerobic, Gram-negative, encapsulated rod. One complete genome 
sequence of A. pleuropneumoniae has been published (strain L20 of serotype 
5b, GenBank accession number CP000569). The genome is 2.3 Mbp in 
length. No plasmid was found in the sequenced strain of the species (Foote 
et al., 2008). For cultivation, A. pleuropneumoniae requires either special 
media such as chocolate agar and pleuropneumoniae-like organism agar   18 
(PPLO); or the supplementation with nicotinamide adenine dinucleotide 
(NAD) or a staphylococcal streak on blood agar for it to grow. Bacteria can 
be cultivated from acutely affected lung tissue, lung abscesses and tonsils but 
overgrowth by other bacteria is common. A. pleuropneumoniae is rarely 
isolated from chronic lesions, but demonstration of A. pleuropneumoniae 
DNA by PCR can be made in subclinically infected animals (Chiers et al., 
2002b). The difficulty to isolate A. pleuropneumoniae from chronically or 
subclinically infected pigs has made serology a valuable tool to study the 
epidemiology of the microbe (Wallgren et al., 1993).  
 6IRULENCEÖFACTORSÖ
A. pleuropneumoniae has a number of different virulence factors as recently 
reviewed (Chiers et al., 2010). The 15 serotypes of A. pleuropneumoniae 
produce different pore-forming repeats in the structural toxin (RTX) 
cytotoxins designated ApxI, ApxII and ApxIII which are cytolytic or 
hemolytic (Table 2). These toxins are secreted by the different serotypes in 
various combinations and determine the virulence of the different serotypes 
by impairing the phagocytic function of both macrophages and neutrophils 
(Bosse et al., 2002). A fourth RTX toxin, ApxIV, is produced by all 15 
serotypes but only after infection, not under in vitro conditions. Pigs infected 
with A. pleuropneumoniae develop specific antibodies directed against ApxIV 
(Dreyfus et al., 2004).  
Table 2. The Apx toxins produced by the different serotype of A. pleuropneumoniae and the 
pathogenicity of these serotypes.  
Apx toxin(s)  Virulence  Serotype 
I + II  High   1, 5ab, 9, 11 (10, 14) 
II + III or II  Moderate  2, 4, 6, 7, 8, 12, 15 (13) 
III Low  3 
 
Other factors which also determine virulence are capsular polysaccharides 
(CPS), lipopolysaccharides (LPS) and outer membrane proteins (OMP) 
(Bandara et al., 2003; Dubreuil et al., 2000). CPS which determines serotype 
specificity protects the bacterium from phagocytosis and complement-
mediated killing. Variations in composition, structure and amount of CPS 
account for variations in virulence as non-encapsulated variants and bacteria 
with thin layers of CPS are less virulent (Bandara et al., 2003; Dubreuil et al., 
2000). On the other hand, similarities in CPS together with the type of 
toxins produced, account for the cross-reactivity observed between different 
serotypes.   19 
 
LPS are essential structural components found in the cell membrane of 
Gram-negative bacteria. Most LPS are composed of three regions; the lipid 
A, the core oligosaccharide and the O-polysaccharide and are denoted as 
smooth. Strains that have lost the O-polysaccharide are classified as rough 
(Dubreuil et al., 2000). An intermediate form, semi-rough, also exists. The 
composition and structure of the LPS O-side chains are specific for most 
serotypes. The virulence exerted by LPS is through its ability to induce the 
production of pro-inflammatory cytokines (Ramjeet et al., 2005) and its 
adhesive properties allowing for A. pleuropneumoniae to adhere to porcine 
respiratory tract cells and mucus. Mutations in LPS have been associated 
with a reduced capability to adhere. 
 
OMP profiles differ between serotypes of A. pleuropneumoniae but there are 
some OMPs which are present in almost all serotypes (Ramjeet et al., 2008). 
Conserved OMPs between serotypes include transferring-binding protein 
(TfbA), a 42-kDa protein, the 14-kDa peptidoglycan-associated lipoprotein 
(PalA) and the 50-kDa lipoprotein OmlA. OMPs play a role in iron-
acquisition and since iron is essential for the growth of A. pleuropneumoniae, 
there are several iron-acquisition mechanisms designed to obtain iron from 
the host. Extracellular iron in the host is bound to the glycoproteins 
lactoferrin and transferrin while intracellular iron is mainly found in 
hemoglobin (Jacques, 2004). 
 
Other virulence factors include proteases, ureases, fimbriae and superoxide 
dismutase. Proteases can degrade IgA and hemoglobin when released from 
A. pleuropneumoniae. Urease which may increase intracellular survival and 
impair macrophage function, is produced by most strains of A. 
pleuropneumoniae  (Chiers  et al., 2010). Fimbriae are involved in the 
attachment of bacteria to epithelial cells of the respiratory system (Bosse et 
al., 2002). 
 0ATHOGENESISÖANDÖIMMUNOLOGYÖ
Although  A. pleuropneumoniae can be detected in tonsils of infected pigs 
(Vigre et al., 2002; Chiers et al., 1999), its main site of action is in the lower 
parts of the respiratory tract which it colonizes after inhalation. Here, 
adhesion to mucus, proteins, ciliated cells of bronchioli and alveolar 
epithelial cells occurs. Adhesion involves virulence factors such as fimbriae, 
LPS and OMP (Chiers et al., 2010). In the lower respiratory tract, A. 
pleuropneumoniae causes extensive tissue damage, often being fatal. The tissue   20 
damage is caused by a number of factors. As nutrients are scarce in the lower 
respiratory tract, A. pleuropneumoniae has developed a number of mechanisms 
for obtaining nutrients from its host that also determine the virulence of A. 
pleuropneumoniae. Secreted LPS and RTX toxins induce lysis of alveolar 
epithelial cells, endothelial cells, red blood cells, neutrophils and 
macrophages, whereby necessary nutrients are released to the environment, 
but also resulting in tissue damage (Chiers et al., 2010). 
 
The immune system of the pig is crucial in the defence against invading 
pathogens. The first line of defence against infections with A. 
pleuropneumoniae is the mucosa of the respiratory tract which traps and then 
removes invading bacteria. However, when bacteria reach the lower 
respiratory tract, they adhere to epithelial cells by LPS (Auger et al., 2009). 
LPS and RTX toxins induce lysis of alveolar epithelial cells, endothelial 
cells, red blood cells, neutrophils and macrophages, resulting in extensive 
tissue damage (Chiers et al., 2010). Further, the RTX toxins produced by A. 
pleuropneumoniae will impair the phagoycytic function of the pulmonary 
intravascular macrophages (Frey, 2003; Haesebrouck et al., 1997). 
 
The tissue damage that arises from the released toxins results in an increased 
accumulation of neutrophils in lung tissue (Abraham et al., 2000) and the 
activation of macrophages and dendritic cells. These cells respond by 
synthesizing and secreting cytokines and other pro-inflammatory molecules 
that trigger inflammation. Important cytokines include interleukin 1 (IL-1) 
(Baarsch et al., 2000), tumor necrosis factor  (TNF-) (Huang et al., 1999), 
IL-6 (Johansson et al., 2001; Fossum et al., 1998) and Il-8 (Bosse et al., 2002; 
Baarsch et al., 2000). In turn, the inflammatory lipids prostaglandins and 
leukotrienes are released, leading to fever and the synthesis of acute-phase 
proteins in the liver (Petersen et al., 2004). TNF- triggers the local release 
of chemokines and cytokines which in turn promotes the adherence, 
migration and activation of leukocytes, primarily neutrophils at the site of 
tissue damage (Huang et al., 1999). A transcriptional analyse of lung tissue 
revealed that IL-1, IL-1, IL-6 and IL-8 were upregulated in lungs 
infected with A.  pleuropneumoniae serotype 5B whereas IL-10 and IFN- 
were downregulated. In addition, mRNA for a number of chemokines as 
well as for complement components and acute-phase proteins were clearly 
upregulated (Mortensen et al., 2009).   21 
Acute-phase proteins 
Acute-phase proteins are mainly synthesized in the liver in response to 
inflammation, infection and tissue damage (Murata et al., 2004; Petersen et 
al., 2004) although local production in other organs such as the lung has 
been described (Phatsara et al., 2007). Acute-phase proteins have been 
studied aiming to find an objective tool for measuring the influence of 
rearing conditions (Amory et al., 2007), monitoring the progression of 
infections (Sorensen et al., 2006; Knura-Deszczk et al., 2002; Heegaard et al., 
1998), efficacies of different treatments (Hulten et al., 2003; Lauritzen et al., 
2003) and the general health status of pig herds (Petersen et al., 2002).  
 
Important acute-phase proteins in the pig include serum amyloid A (SAA), 
haptoglobin, Pig major acute-phase protein (Pig-MAP) and C-reactive 
protein (CRP). The acute-phase proteins both act as stimulators and 
suppressors of inflammation. The different acute-phase proteins have 
different functions where haptoglobin has a bacteriostatic effect by binding 
to hemoglobin in order to prevent the loss of iron (Petersen et al., 2004). 
Serum amyloid A (SAA) is believed to possess various inhibitory functions of 
the inflammatory response (Petersen et al., 2004) and mannan-binding lectin 
(MBL) plays a role in the innate immune response by binding to bacteria 
(Lillie et al., 2006) and activating the complement pathway (Juul-Madsen et 
al., 2006). Pig-MAP is an acute-phase protein expressed in response to acute 
inflammation in pigs (Gonzalez-Ramon et al., 1995; Lampreave et al., 1994). 
Antibodies 
One important role of antibodies is to neutralize toxins and impair 
attachment of bacteria to epithelial cells. Humoral immunity with antibody 
production is considered to be of major importance in the defence against 
A. pleuropneumoniae-infections, both locally and systemically (Krejci et al., 
2005; Nechvatalova et al., 2005; Cruijsen et al., 1995b). Antibodies are 
mainly secreted from plasma cells situated in regional lymph nodes and in 
the submucosa of the respiratory tract.  The local antibody response 
following stimulation with A. pleuropneumoniae-antigen can be detected in 
bronchoalveolar lavage fluid (BALF) (Faldyna et al., 2005; Krejci et al., 2005; 
Nechvatalova et al., 2005; Hensel et al., 1995) and the systemic response in 
serum. As A. pleuropneumoniae is toxigenic, not only the bacteria but also the 
toxins need to be neutralized (Cruijsen et al., 1995b). Toxin neutralization 
occurs when antibodies prevent toxin from binding to receptors on target 
cells (macrophages).   22 
There are five isotypes of porcine immunoglobulins; IgG, IgM, IgA, IgE 
and Ig D with six subisotypes of porcine IgG and two subisotypes of IgA 
(Butler et al., 2009). IgG is the predominant immunoglobulin in serum (35 
mg/mL), constituting more than 80% of the total amount of the serum Igs 
in pigs (Roth, 2006). IgG is important in the systemic defence against 
pathogens. It is the smallest immunoglobulin composed of two identical 
light chains and two heavy chains. It can easily leave blood vessels and enter 
inflamed tissues where it binds to antigens of A. pleuropneumoniae causing 
agglutination and opsonisation (Crawley & Wilkie, 2003). IgG is most 
abundant in the upper parts of the respiratory tract (Wilkie, 1982).  
 
IgA is the major immunoglobulin of mucosal surfaces (53.6 g/mL in 
BALF) and only exists at low levels in serum (1.3 mg/mL)(Butler et al., 
2009). It is secreted as a dimer and is essential in the protection of the 
respiratory tract. IgA cannot activate the classical complement pathway, nor 
can it act as an opsonin. It may however agglutinate antigens thus preventing 
the adherence of pathogens to cells of the respiratory tract (Roth, 2006). IgA 
predominates in the upper part of the respiratory tract (Wilkie, 1982).  
 
IgM exists as a pentamer and is the second most common immunoglobulin 
in serum (6.5 mg/mL)(Butler et al., 2009). IgM is the major 
immunoglobulin produced during a primary immune response. Due to their 
large size, IgM rarely enters sites of local inflammation (Roth, 2006). 
 
IgE is like IgA produce locally by plasma cells located beneath body surfaces. 
IgE trigger inflammation by binding to receptors on mast cells and basophils 
which in turn release inflammatory mediators. IgE confers immunity to 
parasites and is involved in Type I hypersensitivity reactions (Roth, 2006). 
The role of IgD in pigs yet remains unclear (Butler et al., 2009). 
 
Antibodies act in different ways to remove bacteria from the airways and 
inactivate toxins. By binding to antigenic structures on the surface of A. 
pleuropneumoniae antibodies act as opsonins facilitating phagocytosis of the 
bacteria. Antibodies directed to bacterial toxins, bind toxin and neutralize 
them (Cruijsen et al., 1995b). A. pleuropneumoniae has on the other hand 
developed mechanisms to evade antibody mediated defences. It secretes 
proteases which degrade IgG and IgA but it is not known if these proteases 
impair adhesion, opsonisation or toxins (Chiers et al., 2010). Although A. 
pleuropneumoniae is opsonised by antibodies specific for CPS, complement-
mediated killing is not induced and A. pleuropneumoniae is protected by the   23 
CPS and LPS from phagocytosis and complement-mediated killing (Chiers 
et al., 2010; Bandara et al., 2003; Bosse et al., 2002). 
 
Once a pig has developed an acquired immunity towards A. 
pleuropneumoniae, it will respond more rapidly and efficiently compared to 
the first encounter with a particular microbe (Krejci et al., 2005). 
Fetal and Maternal immunity 
The placenta of the sow is of the epitheliochorial type which prevents 
passage of immunoglobulins. The pig fetuses should develop in a sterile 
environment in the uterus, but they are capable of mounting an immune 
response from around 55 to 70 days of gestation (Sinkora & Butler, 2009; 
Tlaskalova-Hogenova et al., 1994). Thus, piglets are capable of mounting an 
immune response at birth when they will encounter a multitude of different 
microorganisms. However, this capacity is limited and takes time. 
Therefore, piglets are dependant on receiving antibodies via colostrum 
directly after birth for survival. 
 
Sow colostrum contains 21.2 mg/mL IgA, 9.1 mg/mL IgM and 95.0 
mg/mL IgG (Butler et al., 2009). As the levels of antibodies obtained by 
piglets vary depending on the immune status of the sow, this may imply that 
piglets derived from sows with higher level of antibodies may be better 
protected since they will receive higher amounts of antibodies via colostrum 
(Damm et al., 2002; Wallgren et al., 1998). The transfer of preformed 
antibodies from immune sows to naïve piglets will confer an immediate but 
temporary immunity in the piglets. This immunity will persist until the 
passively derived antibodies have been catabolised.  
 %PIDEMIOLOGYÖANDÖCLINICALÖSIGNSÖ
The first report of pneumonia in pigs associated with A. pleuropneumoniae, or 
Haemophilus parainfluenzae as it was named then, was made in 1957 (Pattison 
et al.). In 1961, a severe outbreak of respiratory disease in Argentinean pigs 
was associated with A. pleuropneumoniae was described (Shope, 1964). The 
disease symptoms described agree well with those observed in acute 
outbreaks of today. 
 
Clinical signs include per acute deaths without recording of any preceding 
symptoms, most often observed during the fattening period. In acute cases, 
forced breathing with an increase in frequency, sitting posture and fever of 
more than 40° C are common signs. If pigs with severe signs are left   24 
untreated, death usually follows within the next few days. Less severely 
affected animals may recover and the course of disease becomes chronic. In 
the chronic stage of disease, pigs may cough intermittently; appetite may be 
reduced and there is little or no fever (Gottschalk 2006). The severity of the 
disease depends on the age when pigs become infected (Sebunya et al., 
1983), their state of immunity (Krejci et al., 2005; Nechvatalova, 2005; 
Cruijsen et al., 1995b), the environment (Beskow, 2008; Beskow et al., 
1998), season (Maes et al., 2001), infectious dose (Velthuis et al., 2002; Vigre 
et al., 2002; van Leengoed & Kamp, 1989; Sebunya et al., 1983) and which 
serotype the pigs encounter (Rosendal et al., 1985).  
 
Herds become infected by either the purchase of carrier animals or by poor 
biosecurity measures (Maes et al., 2001). Once an infection becomes 
established, further transmission of the infection mainly occurs by pig-to-pig 
contact (Velthuis et al., 2002; Jobert et al., 2000; Savoye et al., 2000). The 
infection is generally associated with high morbidity and varying mortality 
rates when first introduced, but as immunity on herd level develops, the 
course of disease becomes more chronic in character. The animals which 
were only subjected to low doses or survived the initial infection become 
subclinical carriers and will make the infection endemic on herd level 
(Velthuis et al., 2002). 
 
Apart from direct transmission, there are reports on transmission over short 
distances by aerosol under experimental conditions (Kristensen et al., 2004; 
Jobert et al., 2000). It has also been demonstrated that within herd 
transmission occurs between separate units in large herds housing several age 
categories within the same building despite employing all-in all-out 
management within each unit of the building (Nielsen, 2000).  
 
Another important transmission route is from sow to offspring, and piglets 
may harbour A. pleuropneumoniae in their tonsils already at 11 days of age 
(Vigre et al., 2002). Although disease rarely occurs at this age due to the 
presence of maternal antibodies (Cruijsen et al., 1995a; Cruijsen et al., 
1995b; Nielsen, 1995), the piglets may transmit the infection to non-
immune pigs later on during production when maternal immunity wanes 
(Chiers et al., 2002a; Vigre et al., 2002). This is reflected by an increase in 
the cumulative proportion of pigs harbouring A. pleuropneumoniae in their 
tonsils between the age of four to 12 weeks (Vigre et al., 2002). 
   25 
Production systems also greatly influence transmission and the outcome of 
A. pleuropneumoniae infections. All-in all-out production systems have 
proven very effective in reducing the impact of respiratory disease caused by 
A. pleuropneumoniae while continuous systems predispose for outbreaks of 
respiratory disease (Cleveland-Nielsen et al., 2002; Ice et al., 1999). Disease 
manifestations also vary over time within production systems which could 
be a seasonal effect or reflect the level of herd immunity (Maes et al., 2001; 
Beskow et al., 1998) Also, the purchase of pigs increase the risk for 
respiratory disease, especially if grower pig are bought from multiple sources 
by fattening herds (Rosendal & Mitchell, 1983). 
 $IAGNOSISÖ
Apart from bacterial cultivation which is considered the “gold standard”, 
there are other ways of diagnosing infections with A. pleuropneumoniae both 
on an individual basis and on herd level (Stark, 2000). This is of importance 
since cultivation is difficult in cases other than acute ones in which the 
bacterium can be isolated from affected lung tissue and possibly in BALF 
(Moorkamp et al., 2008; Palzer et al., 2008) 
 
Serology is commonly used to detect antibodies to A. pleuropneumoniae. 
Antibodies are usually not detectable until two weeks post infection, 
although antibodies to A. pleuropneumoniae may appear already seven days 
post infection (Wallgren et al., 1999a). There are a number of serological 
tests, but cross-reactions between serotypes may limit their usefulness (Table 
3). Antibodies may also be detected in milk samples from sows and from 
muscle fluids, but the antibody concentrations are generally lower than in 
blood (Wallgren & Persson, 2000; Levonen et al., 1994). 
Table 3. Cross-reactivity between different serotypes of Actinobacillus pleuropneumoniae and the 
isolation of these serotypes in Sweden. 
  Actinobacillus pleuropneumoniae serotype 
 
1 2 3 4 
5a, 
5b 
6  7  8  9  10 11 12 13 14 15 
Cross-
reactions 
9, 
11 
- 
6, 
8 
7 - 
3, 
8 
4 
3, 
6 
1, 
11 
- 
1, 
9 
15 -  - 12 
Found in 
Sweden 
-  X  X  X  X  X - - - - - - - - - 
 
The PCR technique combines high sensitivity with high specificity making 
it a valuable tool in diagnosing A. pleuropneumoniae infections. Asymptomatic 
carriers of A. pleuropneumoniae can be identified by analyzing samples   26 
collected from tonsils (MacInnes et al., 2008; Chiers et al., 2002b). The 
PCR technique is also capable of rapid serotyping of A. pleuropneumoniae 
strains (Stark, 2000). However, there are limitations with PCR, as new 
variants of A. pleuropneumoniae may not be detected. This limitation is also 
true for antibody-detecting methods, observed when atypical strains of 
serotype 12 (Blackall et al., 2002) and serotype 5 (Wallgren et al., 2003) 
infected pigs in Australia and Sweden, respectively  
 0REVENTIONÖANDÖCONTROLÖ
Infections with A. pleuropneumoniae can be successfully treated using a range 
of different antimicrobials provided that the isolates are susceptible 
(Herradora & Martinez-Gamba, 2003; Luque et al., 2000; Wallgren et al., 
1999b; Wallgren et al., 1999a; Smith et al., 1991). However, there is an 
increasing number of isolates which are resistant to several antimicrobials 
which may pose a problem in herd health management (Matter et al., 2007; 
Gutierrez-Martin et al., 2006; Chang et al., 2002). Other important methods 
that can reduce the impact of A. pleuropneumoniae infections are cleaning and 
disinfection (Beskow et al., 2008; Beskow et al., 1989). 
 
Passive immunity may play a role in disease prevention of young pigs and 
there is a potential for reducing transmission of A. pleuropneumoniae within 
endemically infected herds (Krejci et al., 2005; Nechvatalova et al., 2005).  
 
In order to control infections with A. pleuropneumoniae, different preventive 
measures have been employed. Depopulation and repopulation with SPF-
animals is a safe method provided that correct biosecurity measures are 
undertaken following repopulation. Attempts to eradicate A. 
pleuropneumoniae in existing herds have been employed with varying degrees 
of success (Stark et al., 2007; Hofmo & Lium, 1998; Larsen et al., 1998). 
Therefore, the employment of age-segregated rearing which has been 
proven successful in reducing the impact of both acute and subclinical 
disease (Tarasiuk & Bzdawka, 2010; Cleveland-Nielsen et al., 2002; Ice et 
al., 1999), probably is the most commonly used measure to control 
actinobacillosis.  
 #ONTROLÖBYÖVACCINATIONÖ
Vaccination can be an efficient method of controlling disease which was 
demonstrated already in 1798 by Edward Jenner when material from 
cowpox lesions were used to protect humans from smallpox and later the 
process was refined by Louis Pasteur (Silvers & Steptoe, 2001). In general, 
vaccination is used to induce immunity towards defined pathogens in naïve   27 
individuals, providing protection against disease. Vaccinations against 
actinobacillosis have also been employed (Ramjeet et al., 2008; Haesebrouck 
et al., 2004; Valks et al., 1996; Beskow et al., 1993; Beskow et al., 1989), but 
have generally not been very effective unless other preventive measures have 
also been undertaken.  
 
In order to achieve optimal protection, an antigenic component of the 
pathogen of interest must be delivered in a fashion so that immunity will be 
induced at the site of infection. Therefore, knowledge of host-pathogen 
interactions is crucial in vaccine development and vaccination of pigs. To 
date, a number of different antigenic components have been used in 
vaccines against A. pleuropneumoniae infections but so far without complete 
satisfaction (Ramjeet et al., 2008; Haesebrouck et al., 2004). The first 
vaccines consisted of heat-killed bacteria or formalin-treated whole cells 
having the advantage of presenting a multitude of antigenic determinants. 
These vaccines were administered intramuscularly since killed bacteria are 
unable to colonize the respiratory tract which is a prerequisite for local 
immunity to develop. Being a respiratory pathogen, local immunity is 
considered to be important in the defence against A. pleuropneumoniae 
infections (Nechvatalova et al., 2005) which may explain the poor efficacy of 
intramuscularly administered bacterins (Ramjeet et al., 2008; Haesebrouck et 
al., 2004).  
 
As lesions to a large extent are caused by the different toxins of A. 
pleuropneumoniae, the Apx toxins together with OMP are considered to be 
major antigens and have consequently been in focus when designing subunit 
vaccines (Ramjeet et al., 2008; Haesebrouck et al., 2004). However, these 
vaccines did not either confer complete protection (Oldfield et al., 2008; 
Van Overbeke et al., 2001). Recent development using live attenuated A. 
pleuropneumoniae-vaccines has showed promising results but are not yet 
commercially available (Maas et al., 2006).   28 
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 !IMSÖÖ
The overall objective of this thesis was to investigate respiratory infections in 
pigs, especially those caused by Actinobacillus pleuropneumoniae, both under 
field and experimental conditions.  
 
More specifically the aims were to: 
 Increase the knowledge on passive immunity to infections with A. 
pleuropneumoniae and how variations in the passive immunity provided 
by the sow via colostrum may influence piglet susceptibility to 
infections and the overall performance of these pigs from birth to 
slaughter. 
 Study the course of A. pleuropneumoniae-infections in relation to the 
protective role of innate and acquired immunity at repeated exposures 
to the pathogen. 
 Obtain further knowledge on how secondary infections with 
Pasteurella multocida may influence the epidemiology of A. 
pleuropneumoniae-infections on herd level. 
 Evaluate potential strategies in preventing and combating infections 
with A. pleuropneumoniae. 
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 #ONSIDERATIONSÖREGARDINGÖ-ATERIALSÖANDÖ
-ETHODSÖ
Considerations regarding materials and methods used in this thesis are 
presented below. Detailed information is given in each paper (I-IV).  
 &IELDÖTRIALSÖ
The studies described in papers I and IV were conducted as field trials. The 
unique conditions of every herd will of course influence the results. This 
will in turn certainly limit to what extent the results can be applied to other 
herds.  
 
Factors which can have an impact on respiratory infections are: herd type 
(specialized piglet producing herd, fattening herd, farrow-to-finish herd), 
production system (continuous or all-in all-out), ventilation system, air 
volume, feeding regimes including feed components, recruitment and 
quarantine policies (Beskow et al., 2008; Cleveland-Nielsen et al., 2002; 
Maes et al., 2001; Ice et al., 1999; Beskow et al., 1998). Also seasonal 
variations are known to play a role in A. pleuropneumoniae-infections (Maes et 
al., 2000). These factors may also change over time. Therefore, the results 
obtained in field trials should be applied with care to other herds. Still, field 
trials are required to test hypothesis and the effect of remedial measures 
under real life conditions. 
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 %XPERIMENTALÖTRIALSÖ
Experimental trials allow for controlled conditions surrounding the factors 
investigated. Thus, the results obtained are more likely to truly reflect the 
parameters investigated (Papers II and III). However, when the same 
parameters are investigated under field conditions, the outcome may be 
different since a number of other variables are likely to interact with the 
investigated variable thereby influencing the results.  
 
Experimental trials are often very costly due to rigorous biosecurity demands 
which also put limitations on the size of research facilities suitable for 
experimental trials. This will limit the numbers of animals that can be used 
in a trial, especially if several trial groups are used which the case for the 
experimental trial was, described in papers II and III. A small number of 
animals can result in great standard deviations in which true significant 
differences may be obscured by the out-layers. 
 
Figure 2. View of the research facilities at SVA. This group of pigs had been treated with 
tetracycline after an inoculation with Actinobacillus pleuropneumoniae and was later reinoculated 
with the same strain (Papers II and III).   33 
 3ELECTIONÖOFÖHERDSÖANDÖANIMALSÖ
 0APERÖ)Ö
For the study described in paper I, a farrow-to-finish herd suffering from an 
endemic infection with A. pleuropneumoniae was selected.  The herd 
investigated weaned their piglets at the age of six and a half weeks which 
was later than the average weaning age (33.9 days) in Sweden. After 
weaning, piglets were kept in their pen of birth until the age of nine weeks. 
More commonly piglets are either transferred to a growing unit at weaning, 
or kept in the combined farrowing-growing pens until they are either sold 
or transferred to the fattening unit.  
 
The production was age segregated until the age of nine weeks, but after 
that it was continuous although pigs were housed batch-wise. Pigs of 
different ages were not mixed in the pens. At the age of 16 weeks, the 
growers were transferred to the fattening unit housing five different age 
categories. Neither in the fattening unit were pigs of different ages mixed on 
pen level. The continuous production system contributed to the endemic 
disease situation as it has been shown that all-in – all-out production has 
greatly reduced the impact of respiratory infections (Cleveland-Nielsen et al., 
2002; Ice et al., 1999).  
 
The sows of paper I were selected with the aim of obtaining dams which 
differed in serum antibody concentrations to A. pleuropneumoniae within the 
same batch of sows. Pregnant gilts were excluded in order to avoid animals 
with an active, ongoing infection. As runts are more likely to die before 
weaning, these animals were excluded with the aim minimizing loss of 
animals during the trial.  
 0APERSÖ))ÖÖ)))Ö
The selection of the pigs used for the experimental trial was based on the 
health status and age of the pigs. As it was necessary to use pigs previously 
un-exposed to A. pleuropneumoniae in order to be able to study the primary 
immune response, SPF pigs were required. The pigs were nine weeks old 
when arriving at the research facilities and 10 weeks when they were 
inoculated in order to correspond to the age when pigs in conventional 
herds are usually allocated to fattening herds/units and thereby risk being 
subjected to infections with A. pleuropneumoniae (Andreasen et al., 2000; 
Wallgren et al., 1993).   34 
 0APERÖ)6Ö
The herd selected for the study described in paper IV, was a good 
representative of a modern specialized fattening herd in Sweden having 
good production records and being well-managed. As it had experienced an 
acute outbreak of actinobacillosis recently, it was possible to test preventive 
measures in the form of vaccinations in a controlled manner under field 
conditions. 
 
The herd was monitored for two years, and during this time the suppliers of 
growers changed. As infectious pressures vary between herds, this may have 
influenced the epidemiology in the fattening herd. During the time period 
when pigs were vaccinated twice, all sampled animals were seronegative on 
arrival while six sampled pigs were seropositive already on arrival when pigs 
were vaccinated three times. The suppliers of growers were different during 
these two periods which most likely influenced the results. This on the other 
hand, reflects pig production as it organized in Sweden today. 
 )SOLATEÖUSEDÖFORÖINOCULATIONÖ
A. pleuropneumoniae serotype 2, strain NVI 700/89, was used for the 
experimental study described in papers II and III. Serotype 2 is the 
predominant serotype found in Sweden and the isolate used was cultivated 
in 1989 from a clinical case of acute actinobacillosis. The strain belongs to a 
clone which is still dominating in Sweden as confirmed by pulsed-field gel 
electrophoresis (PFGE) (Aspàn & Wallgren, 2008). This particular strain has 
previously been used in other experimental studies (Wallgren et al., 1999b; 
Wallgren et al., 1999a). An inoculation dose which would induce acute 
actinobacillosis without killing the pigs could therefore be used. Since the 
strain belonged to the predominant serotype in Sweden, it did add strength 
to the results although these were obtained from an experimental study.  
 $IAGNOSTICÖMETHODSÖ
 %NZYME
LINKEDÖIMMUNOASSAYÖ%,)3!	Ö
Antibody levels to A. pleuropneumoniae serotype 2 were detected by an 
indirect ELISA system detecting the total amount of Ig’s (Wallgren & 
Persson, 2000). In brief, the ELISA is based on a phenol-water extract of an 
A. pleuropneumoniae serotype 2 isolate which is used as the coating antigen. 
The antigen contains no proteins. The cut-off value for a positive reaction   35 
in sera diluted 1/1000 in PBS-T was defined as A450=0.50. When a cut-off 
value of 0.50 (A450) is used, the ELISA has a high specificity (99%) and high 
sensitivity (97%) (Wallgren & Persson, 2000). This implies that also low 
responding pigs will be detected with this ELISA. 
 
The ELISA used detects LPS and CPS antigens which pigs produce large 
amounts of antibodies against. Although LPS antigens are considered to be 
serotype-specific, there are antigenic similarities which cause cross-reactivity 
in serological assays (Dubreuil et al., 2000) (Table 3).  
 !CUTE
PHASEÖPROTEINSÖ
SAA and haptoglobin were analysed using commercial assays. These assays 
have been validated in intra and inter assay tests (Tecles et al., 2007). The 
coefficients of variation were low for the haptoglobin assays when samples 
obtained from both SPF and diseased pigs were analysed. In contrast, there 
was a large coefficient of variation for the SAA assays. It would therefore 
have been worthwhile to have analysed the samples from the experimental 
trial (Paper III) in duplicates. However, a clear response was detected for 
both of these acute-phase proteins in the experimental trial described in 
paper III.  
 
According to the manufacturer, haptoglobin levels up to 2.2 mg/mL are 
considered to be within the normal range and samples which are classified as 
acute are within the range of 3.0 to 8.0 mg/mL. The highest level of 
haptoglobin obtained in the trial (Paper III) was from the most severely 
diseased pig but it did only reach 2.02 mg/mL. Still, there was a clear 
difference in serum levels of haptoglobin between diseased and non-diseased 
pigs which makes the test results valid although they were of a lower 
magnitude. The highest SAA concentrations in the experimental trial were 
on the other hand greater than the reference range provided by the 
manufacturer (62.5 – 1000 g/mL). Although the observed differences 
between the results obtained in the experimental trial and the concentrations 
suggested by the manufacturer, this test was considered to be useful in 
assessing A. pleuropneumoniae infections in SPF pigs as there were definite 
increases in SAA following the inoculations of naïve animals. 
 
Pig-MAP was analysed according to a previously described protocol 
(Gonzalez-Ramon et al., 1995; Lampreave et al., 1994) and not with the 
commercially available test that has been validated (Tecles et al., 2007). The 
concentrations obtained in SPF pigs in the experimental trial (Paper III)   36 
were lower compared to concentrations obtained from eight-week old pigs 
in commercial Spanish herds (Pineiro et al., 2009). Most likely this 
difference mirrors the difference in health status between these two groups 
of pigs.  
 
Porcine MBL described in paper III, is the most recently identified of the 
acute-phase proteins investigated and there is no commercial assay available 
for the analysis of pMBL. The samples analysed in paper III exhibited a large 
variation in serum concentrations of pMBL. This difference was not 
considered to be due to variations in the assays as similar variations have 
been described previously and attributed to differences in heritability 
between breeds (Juul-Madsen et al., 2006). The divergent samples were re-
analysed one or two more times but continued to have deviating values. 
Thus the low values obtained for these samples were considered to be true.  
 !NTIMICROBIALSÖ
The selection of antimicrobials used in the experimental trial described in 
papers II and III, was based on prior knowledge of treatment efficacies of 
antimicrobials against A. pleuropneumoniae-infections (Lauritzen et al., 2005; 
Herradora & Martinez-Gamba, 2003; Lauritzen et al., 2003; Luque et al., 
2000; Wallgren et al., 1999b; Wallgren et al., 1999a; Smith et al., 1991).  
 
Enrofloxacin was selected for its reported superior efficacy in treating 
infections with A. pleuropneumoniae (Herradora & Martinez-Gamba, 2003; 
Wallgren et al., 1999b; Wallgren et al., 1999a). Tetracyclines have also been 
used as in-feed medications with reported good results (Luque et al., 2000). 
Penicillin has been used to treat actinobacillosis in clinical practice with 
reportedly good results
1
 
, but has in experimental trials been less efficacious 
(Wallgren  et al., 1999a). There are no reports of clinical trials where 
penicillin is used for treating A. pleuropneumoniae-infections but, amoxycillin 
has been reported efficacious in treating actinobacillosis (Lauritzen et al., 
2005).  
The minimal inhibitory concentration (MIC) using broth microdilution 
according to the recommendations of the National committee for clinical 
laboratory standards (NCCLS) was determined for the isolate (A. 
pleuropneumoniae  serotype 2 NVI strain 700/89) used for inoculation 
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(Wallgren et al., 1999b; Wallgren et al., 1999a). The MIC values were 
determined to 0.5 g/mL for penicillin, 0.25 g/mL for enrofloxacin and 
1.0  g/mL for oxytetracycline (Wallgren et al., 1999a). With these MIC 
values, the isolate used was considered sensitive to the antimicrobials used 
for treatment.  
 
In this way, differences observed for the parameters studied could be directly 
linked to the pharmacological properties of the antimicrobial used for 
treatment. A broad range of efficacies was chosen in order to investigate 
how this affected the immune responses. 
 6ACCINEÖÖVACCINATIONÖTIMEÖPOINTSÖÖ
The vaccine, Porcilis® APP vet. (Intervet, Boxmeer, the Netherlands), used 
in the study described in paper IV, is the only commercial vaccine against A. 
pleuropneumoniae  currently available in Sweden (FASS vet., 2010). It is a 
subunit vaccine which contains OMP proteins, the Apx toxoids; Apx I, Apx 
II and Apx III, together with dl--tochopherolacetate as adjuvant. These 
antigens are considered to be major virulence factors of A. pleuropneumoniae 
and have therefore been considered as important components in vaccines 
(Ramjeet et al., 2008). However, the vaccine has been used rather sparsely, 
possibly due to its reported limited efficacy (Ramjeet et al., 2008; 
Haesebrouck et al., 2004; Chiers et al., 1998).  
 
Reduced vaccine efficacy could have a number of explanations, some of 
which may be due to incorrect handling including incorrect administration 
and/or incorrect storage temperature. As it was possible to control for, these 
parameters were ruled out as causes of reduced vaccine efficacy.  
 
The time-point for administration could be discussed. In the trial described 
in paper IV, pigs were vaccinated on arrival at the fattening herd. The age 
when pigs are brought to a fattening herd varies but ranges from eight to 14 
weeks. According to the product details of the vaccine, the vaccine should 
be administered at the age of six and 10 weeks to ensure that pigs are 
vaccinated before they are likely to become infected. However, when pigs 
are bought from different piglet producers, it is not always known in 
advance which herds these pigs originate from. This makes it difficult to 
vaccinate pigs at the stipulated ages unless you raise your own pigs. 
Vaccinations against A. pleuropneumoniae are therefore usually performed 
when pigs arrive at the fattening herds.   38 
Another limitation is that the efficacy of the vaccine is reported to be of 
short duration (FASS vet., 2010). The serological response measured after 
vaccination was greatest two weeks post vaccination and declined thereafter 
(Ridremont et al., 2006). This implies that antibody level will be greatest at 
the time-point of arrival to a fattening herd if pigs are vaccinated at the age 
of six and 10 weeks. Further, the antibody levels will decline during the 
fattening period indicating a reduced protection during the later stages of 
rearing. Depending on the infection dynamics of the herd, pigs may be 
unprotected to A. pleuropneumoniae infections although they have been 
vaccinated (Andreasen et al., 2000). 
 
Another aspect on the study described in paper IV, was the decision to 
vaccinate entire batches under a period of time and then completely cease 
with the vaccinations for a period of time. In order to be able to compare 
the effect of vaccinations on performance it would have been desirable to 
vaccinate half the batch and leave the other half as a control. However, as 
respiratory pathogens may spread between units in large herds housing 
several age categories within the same building despite all-in all-out 
management (Nielsen et al., 2000), it was decided that all pigs under a 
defined time period would be vaccinated and that adjacent time periods 
when no vaccinations were employed would serve as control periods.  
 3LAUGHTERÖREGISTRATIONSÖ
Registrations made in the post mortem inspection of carcasses at slaughter 
provide valuable information on the lung health status of a herd. However, 
pleuritis registrations do not provide information on the etiologic cause of 
the lesions (Jirawattanapong et al., 2009). Further, if a lung pluck is 
registered for pleuritis, there is no indication on the extent of the lesions. All 
lesions larger than two centimetres in diameter will be classified as pleuritis. 
This means that a pleurisy lesion covering most of the lung lobes will have 
the same dignity as the smallest lesion recorded in slaughter registrations. 
The slaughter registrations will therefore provide little information on the 
severity of disease on herd level. Thus, a herd registered for 30% pleuritis 
will not necessarily be more severely affected than a herd registered for e. g. 
15% pleuritis. However, slaughter registrations together with production 
parameters such as daily weight gain (DWG) will be useful in assessing 
respiratory disease on herd level.   39 
 3TATISTICALÖANALYSESÖ
As the majority of data and variables analyzed were non-normally 
distributed, the Wilcoxon Rank Sum test was used in the statistical analyses 
of continuous data (Papers I, III and IV). Differences between experimental 
groups in the whole blood culture stimulatory response described in paper 
III were analyzed for each sampling day using the Mann-Whitney test. 
Non-continuous data were categorized and analyzed using the Fischer’s 
Exact test (Paper IV). Area-under-curve (AUC) calculations for blood 
parameters for every individual over three-day periods, except the last 
period which contained four days, were used when groups were compared 
as described in paper III. 
 
In Paper II, t-test was used for comparison between recordings made at 
group level or once per pig. An analysis of variance (PROC MIXED) was 
applied to variables that were recorded for individual pigs’ data. The 
statistical model included fixed effects of group, sex, time period and 
sampling day within time period, and the interaction between group and sex 
and between group and time period. The statistical model also included the 
random effect of pig, nested within group/sex combinations. Least square 
means were estimated and compared using a t-test.   40 
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 -AINÖ2ESULTSÖANDÖ$ISCUSSIONÖ
The resistance of individual pigs to infections with A. pleuropneumoniae 
depends on a number of variables and starts even before they are born. 
Serum concentrations of antibodies to A. pleuropneumoniae serotype 2 were 
found to decrease during the last month of gestation among sows with high 
serum antibody concentrations (Paper I) which was in accordance with 
previous findings (Klobasa et al., 1985). Antibodies are transferred from 
serum to the mammary gland (Salmon et al., 2009), and higher levels of 
colostral antibodies were detected in colostrum of sows with high levels of 
serum antibodies than in colostrum of sows with low levels of serum 
antibodies (Paper I), which has also been shown for other microbes (Damm 
et al., 2002; Wallgren et al., 1998). Thus, the levels of antibodies in 
colostrum appear to be related to the levels of serum antibodies, which 
indicate that the concentration of colostral antibodies can be enhanced 
through prior stimulation of systemic immunity of the sows. This implies 
that there are ways to improve immunity in neonatal pigs. 
 
Although actinobacillosis is usually seen in growers and fatteners it may be 
beneficial to increase the levels of serum antibodies in pregnant sows with 
the aim of improving the colostral transfer of antibodies to the offspring. 
However, this must be performed so that clinical disease is not induced. 
Passively derived immunity has been shown to play an essential role in the 
protection against disease in piglets (Krejci et al., 2005; Nechvatalova et al., 
2005), and it has been demonstrated that higher levels of antibodies in 
colostrum will prolong the period in which passively derived antibodies can 
be detected in serum from piglets (Damm et al., 2002; Wallgren et al., 
1998). This was now also confirmed for A. pleuropneumoniae (Paper I), 
which appears to be of clinical relevance because it has been demonstrated   42 
that antibody levels influence the level of protection against A. 
pleuropneumoniae (Cruijsen et al., 1995b). 
 
It has been demonstrated that piglets may harbour A. pleuropneumoniae in 
their tonsils already at an age of 11 days (Vigre et al., 2002) and as 
vaccination of young piglets against A. pleuropneumoniae at the age of two 
and five weeks did not affect the susceptibility (Velthuis et al., 2003), it may 
be beneficial to increase the passive immunity of piglets. This could possibly 
reduce the number of subclinical carriers, thereby reducing transmission of 
the infection between young piglets.  
 
It is however not known whether a high level of passive immunity really 
will reduce the number of subclinical carriers. Nor if the duration of the 
passively derived immunity would last long enough to be effective when 
pigs first encounter the pathogen, which is likely to occur at the age of 9 to 
12 weeks. This age coincides with the time when maternal immunity 
generally has declined to low levels leaving pigs relatively unprotected to 
infections (Chiers et al., 2002a; Cruijsen et al., 1995c; Gardner et al., 1991). 
This age also corresponds to the age when pigs from different sources are 
brought together in specialized fattening herds and the age when A. 
pleuropneumoniae  is most readily isolated from the upper respiratory tract 
(Wongnarkpet et al., 1999; Willson et al., 1987). If unprotected pigs are 
mixed with subclinical carriers, there is an increased risk for disease, both 
among the unprotected pigs and the carriers  (Velthuis et al., 2002). 
 
A common method to enhance systemic immunity is by vaccination against 
the pathogen of interest. It has been demonstrated that the offspring to 
vaccinated sows expressed higher antibody levels to A. pleuropneumoniae until 
the age of 10 weeks compared to the offspring of unvaccinated sows (Bak et 
al., 1998). Possibly, vaccination of sows could provide piglets with enough 
antibodies until the age when they most likely encounter the infection. 
However, the offspring to the vaccinated sows were less responsive to a 
natural infection producing smaller amounts of antibodies compared to the 
offspring of unvaccinated sows (Bak et al., 1998). In accordance, the 
offspring to the sows with high levels of antibodies to A. pleuropneumoniae 
serotype 2 seroconverted at a later time point than the offspring to sows 
with low antibody levels (Paper I). In contrast, they mounted higher levels 
of serum antibodies toward A. pleuropneumoniae when they seroconverted. 
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The influence of passively derived immunity on the levels of Ig isotypes in 
serum and BALF following exposure to A. pleuropneumoniae has been shown 
by others. Piglets that had received colostrum produced an IgM response in 
serum indicative of a primary immune response following a low-dose 
challenge with A. pleuropneumoniae at four weeks of age. However, the 
response was weaker compared to the response seen in piglets that had not 
received colostrum prior to the low-dose challenge (Nechvatalova et al., 
2005). The same pattern was also observed for serum IgG antibodies. In 
BALF, an increase in IgA antibodies was only detected in pigs which had 
not received colostrum when challenged. There was on the other hand an 
increase in BALF IgG, regardless if the piglets had received colostrum or not 
prior to the low-dose challenge. Still, piglets that had received both 
colostrum and a low-dose infection (which resemble the natural transmission 
dynamics) were best protected against a high-dose challenge (Krejci et al., 
2005; Nechvatalova et al., 2005). 
 
In paper I, the seroconversion to A. pleuropneumoniae was in both groups 
followed by increasing levels of serum antibodies to both toxigenic and non-
toxigenic strains of P. multocida, emphasizing the important role of P. 
multocida as a secondary invader (Paper I). 
 
The observed difference in antibody levels to A. pleuropneumoniae serotype 2 
in sows was also reflected in their offspring, i.e. the offspring to sows with 
high levels of serum antibodies to A. pleuropneumoniae also developed high 
levels of antibodies to A. pleuropneumoniae (Paper I). These piglets also 
developed higher levels of antibodies to both toxigenic and non-toxigenic 
strains of P. multocida (Paper I).  This indicates that immune traits are 
heritable, which has also been investigated in detail previously (Mallard et 
al., 1998). Pigs selectively bred for high immune response were shown to be 
more responsive to vaccinations against A. pleuropneumoniae (Magnusson et 
al., 1997). However, high immune responsiveness may be detrimental, as 
pigs of a high immune response line suffered from more severe clinical signs 
after being subjected to a Mycoplasma hyorhinis infection (Magnusson et al., 
1998). 
 
At transfer to the fattening unit, increasing levels of serum antibodies to A. 
pleuropneumoniae were detected both in pigs with high and low initial levels 
of serum antibodies (Paper I). However, at this time without a subsequent 
decrease in weight gain, which indicated that the pigs had developed a   44 
partial or complete protection to reinfections with A. pleuropneumoniae 
(Paper I). 
 
To further explore this possibility, an experimental trial was designed that 
investigated the secondary immune response to A. pleuropneumoniae and how 
this was related to the primary immune response. The development of 
antibodies was associated to the protection against re-infection with A. 
pleuropneumoniae (Papers II and III). 
 
Acute pleuropneumonia continues to be a problem in pig production in 
spite of preventive measures such as batch-wise rearing, biosecurity measures 
et.c. Therefore, the use of antimicrobials is required in order to reduce losses 
in form mortalities and reduced production performance. There are 
numerous studies describing the efficacies of different antimicrobials 
(Herradora & Martinez-Gamba, 2003; Luque et al., 2000; Wallgren et al., 
1999b; Wallgren et al., 1999a; Smith et al., 1991). However, as pigs in 
endemically infected commercial herds are likely to be re-exposed to A. 
pleuropneumoniae, it is desirable that treated pigs also develop a protective 
immunity towards reinfections. Whether this is achieved or not, can depend 
on the efficacy of the treatment used, and on the time point when treatment 
is initiated. 
 
The efficacy of enrofloxacin in treating infections with A. pleuropneumoniae is 
well documented (Herradora & Martinez-Gamba, 2003; Wallgren et al., 
1999b; Wallgren et al., 1999a; Smith et al., 1991). However, there are 
reports on the occurrence of widespread resistance to enrofloxacin among 
clinical isolates in Taiwan (Wang et al., 2010), and also in a few European 
isolates (Hendriksen et al., 2008). Therefore, it is always desirable to evaluate 
MIC-values when medicating with enrofloxacin against actinobacillosis. 
 
Once again, the superior efficacy of enrofloxacin in treating acute 
actinobacillosis was documented (Papers II and III). However, the intiation 
of treatment with enrofloxacin at the very first onset of clinical signs 
appeared to eliminate the bacteria before a specific immune response had 
developed and the pigs were unprotected at reinfection. Consequently, the 
enrofloxacin treated pigs did not differ in clinical signs of disease from the 
previously uninoculated pigs following the second challenge. Acute-phase 
proteins are a part of the innate immune response (Murata et al., 2004; 
Petersen et al., 2004), and the acute-phase response seen at the re-exposure 
to  A. pleuropneumoniae in the previously enrofloxacin treated pigs further   45 
strengthens the observations that these pigs had not mounted a sufficient 
immune response following the first exposure to the microbe to be 
protected at he second exposure (Paper III). 
 
The enrofloxacin treated pigs also differed from the other treated pigs in that 
they had not developed antibodies following the first challenge. On the 
other hand, the tetracycline and penicillin treated pigs as well as the 
untreated pigs had all developed serum antibodies to A. pleuropneumoniae. 
These pigs were unaffected by the second challenge and did not display an 
acute-phase response then (Papers II and III). This implied that an immune 
response was initiated at the first exposure to A. pleuropneumoniae, which was 
mirrored by a seroconversion to A. pleuropneumoniae in these pigs. However, 
the clinical signs in the tetracycline treated group were less prominent than 
in the other inoculated groups and did not differ from the enrofloxacin 
treated group from 44 hours after the first inoculation (Paper II). 
 
Although the A. pleuropneumoniae isolate showed low MIC values for 
tetracycline (Wallgren et al., 1999a), it is surprising that it was almost as 
efficient in reducing the clinical signs as enrofloxacin since tetracycline is 
generally considered to be bacteriostatic in its mode of action (Giguère, 
2006). However, bactericidal activity against A. pleuropneumoniae has been 
demonstrated, but with a slow kill rate which may be of importance for this 
observation (Norcia et al., 1999). Also, the anti-inflammatory properties 
associated with tetracycline may account for its efficacy, partly owing to the 
amelioration of the toxic effects of the LPS released by A. pleuropneumoniae 
(Giguère, 2006). The efficacy of the tetracycline treatment could also be 
seen at necropsy since these pigs had the lowest scores for both pleurisy and 
pneumonia lesions (Paper II). Neither could A. pleuropneumoniae be isolated 
from the sampled tissues 20 days after the second inoculation.  
 
In contrast, A. pleuropneumoniae has been reisolated 17 days after a single 
inoculation in pigs, in-feed medicated with tetracycline initiated prior to the 
inoculation (Wallgren et al., 1999b). It is important that correct doses are 
administered; otherwise there may be a lack of therapeutical effect 
(Hunneman, 1986). Per oral administration of antimicrobials may result in 
large variations in plasma concentrations between animals, possibly 
contributing to the reduced efficacy in preventing the development of 
subclinical carriers (Mason et al., 2009). However, in the present study, the 
development of a protective immunity to A. pleuropneumoniae following the 
first inoculation was manifested as the microbe was not reisolated after the   46 
second challenge in pigs that had been treated with tetracycline after the first 
inoculation with A. pleuropneumoniae (Papers II and III). 
 
Although both enrofloxain and tetracycline were clinically efficacious (Paper 
II), only pigs treated with tetracycline did seroconvert to A. 
pleuropneumoniae. Further, they were protected from disease at the 
reinoculation, and did not mount an acute-phase response then (Paper III). 
The antibody levels to A. pleuropneumoniae did on the other hand increase 
more gradually in the tetracycline treated pigs compared to the antibody 
levels in the penicillin treated group and the inoculated control group. 
Further, the serum antibody level was lower in the tetracycline treated pigs 
than in the other two groups at the end of the trial, but this did not seem to 
influence the level of protection. This was in contrast to a previous report 
indicating that protection against A. pleuropneumoniae was dependent of the 
levels of antibodies (Cruijsen et al., 1995b). However, it could also indicate 
that if a certain threshold level of antibodies to A. pleuropneumoniae is 
reached, this may be sufficient to prevent the development of disease.  
 
Penicillin showed the least efficay in treating clinical actinobacillosis as this 
group did not differ from the inoculated control group in clinical recordings 
until day 15 following the first inoculation (Paper II). However, there was a 
delay in seroconversion with five days compared to the inoculated control 
group, indicating a partial therapeutic effect of the drug. There was no 
increase in clinical signs of disease following the second inoculation. Nor 
was an acute-phase response recorded and the leukocyte counts remained 
unaltered. Consequently, pigs were unaffected by the second inoculation 
which in turn indicated that a protective immunity had developed in these 
pigs, which was further supported by the inability to reisolate A. 
pleuropneumoniae at necropsy. 
 
The previously untreated pigs resembled those treated with penicillin 
following the first inoculation (Paper II). The signs of clinical disease did not 
increase following the reinoculation with A. pleuropneumoniae. This indicated 
that the pigs had developed immunity towards the microbe, as also 
supported by the lack of an acute-phase response (Paper III). 
 
The results obtained indicate that penicillin might not be the best treatment 
choice against A. pleuropneumoniae (Paper II and III). Variable responses to 
treatments with penicillin have also been reported from the USA (Frank et 
al., 1992). There are possible explanations for the poor result reported for   47 
penicillin (Paper II & III). At concentrations eight times the MIC-value, 
penicillin has been shown to inhibit growth of A. pleuropneumoniae for up to 
24 hours (Norcia et al., 1999). As penicillin works in a time-dependant 
fashion, the results may have been different if other treatment strategies had 
been employed. It has been suggested that penicillin needs to be 
administered at 12-hour intervals and at higher doses (25 instead of the 21 
mg/kg bodyweight used in the experimental trial) for serious infections such 
as those caused by A. pleuropneumoniae (Prescott, 2006). This could be 
interesting to investigate, but it should be remembered that the treatment 
strategies employed in paper II and paper III corresponded to the 
recommendations of the manufacturer (FASS vet., 2010). 
 
Acquired resistance should always be considered in cases of treatment failure 
and resistance of A. pleuropneumoniae to penicillin has been reported for a 
number of years from different countries across the world (Hendriksen et al., 
2008; Matter et al., 2007; Gutierrez-Martin et al., 2006). However, all 147 
samples of A. pleuropneumoniae submitted to SVA since 2005 have had MIC 
values   0.5 mg/L and there are no signs of an acquired resistance to 
penicillin (SVARM, 2010). The strain used for the inoculation in the 
experimental trial had an MIC value of 0.5 mg/L (VetMIC, SVA) why this 
strain should be regarded as sensitive to penicillin. 
 
Bearing the above in mind, it should be remembered that penicillin has been 
used with good results for treating acute actinobacillosis in commercial pig 
herds
2
 
, and penicillin has often been considered to be the first choice 
antimicrobial substance in antibiotic policy documents. Possibly, the 
reported efficacy of penicillin in commercial pig herds could be due to pigs 
being exposed to lower infectious doses compared to the inoculation dose 
used in the experimental trial (Paper II and III). Another explanation could 
be that unifactorial infections are rare in practice, as was indicated by the 
serological responses to P. multocida (Paper I). Swedish isolates of P. multocida 
are generally sensitive to penicillin, which could contribute to the treatment 
efficacy reported for penicillin in treating commercial pigs for respiratory 
disease symptoms. 
Still, the results indicate that it could be questioned if penicillin is the drug 
of choice when combating acute A. pleuropneumoniae infections in pig herds. 
Instead tetracycline appears to be an interesting alternative, due to good 
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clinical efficacy, simultaneously allowing a protective immune response to 
develop (Papers II and III). The latter is of great interest in practice, as pigs 
are likely to be re-exposed to the microbe. 
 
Enrofloxacin had a superior efficacy (Papers II and III), but as pigs did not 
mount a protective immunity when treated at an early phase of the 
infection, the drug ought to be saved for treating severely affected animals. It 
could be argued that pigs in commercial herds will probably be treated at a 
later phase of the infection than in the trial presented. The results of the 
tetracycline treated pigs (Papers II and III) indicate that pigs could then 
develop a protective immunity, even when treated with enrofloxacin. This 
is an interesting thought, and ought to be investigated further. Still, 
enrofloxacin should be used judiciously in line with prudent use of 
antimicrobials. Not the least since enrofloxacin, due to its superior efficacy 
ought to be the drug of choice in eradication attempts, and when 
performing other strategic measures with the aim of reducing the pathogen 
load of A. pleuropneumoniae to a minimum in populations known to have 
developed a protective immunity to the microbe. 
 
The first study and the experimental trial both indicated that pigs that had 
developed an immune response to A. pleuropneumoniae also developed partial 
or total immunity towards reinfections with A. pleuropneumoniae (Papers I, II 
and III). This was also in accordance with a number of other studies 
performed over the years which have demonstrated that pigs which were 
exposed to a natural infection were immune to subsequent reinfections 
(Krejci et al., 2005; Nechvatalova et al., 2005; Cruijsen et al., 1995a; 
Cruijsen et al., 1995b; Cruijsen et al., 1995c; Loftager et al., 1993; Bosse et 
al., 1992). Therefore, vaccinations have been considered a tempting way to 
prevent actinobacillosis, but so far have different vaccines and vaccination 
strategies not been very successful (Jirawattanapong et al., 2008; Ramjeet et 
al., 2008; Haesebrouck et al., 2004; Beskow et al., 1993; Beskow et al., 
1989). 
 
The general aim with vaccinations is to establish a level of immunity so that 
pigs can withstand an infection without becoming diseased. When pigs from 
different sources are allocated to a fattening unit, transmission of A. 
pleuropneumoniae from subclinical carriers is likely to occur (Velthuis et al., 
2002; Nielsen et al., 2000; Savoye et al., 2000; Wallgren et al., 1993; 
Artursson et al., 1989). This also applies to pigs from a single source if they 
are allocated to facilities housing several different age groups as transmission   49 
of  A. pleuropneumoniae may occur between units even though each age 
group is reared on an all-in all-out basis (Nielsen et al., 2000). Therefore 
vaccinations against A. pleuropneumoniae were investigated in a fattening herd 
affected first by subclinical infections with A. pleuropneumoniae reflected in 
the slaughter registrations and then later by acute outbreaks of 
actinobacillosis. Prior to the initiation of the vaccinations, it was concluded 
that the pigs were seronegative to A. pleuropneumoniae on arrival to the herd 
at an age of approximately nine to 12 weeks. Therefore, pigs were not 
considered to have an active infection on arrival. However, as stress may 
cause a subclinical infection to be activated (Roth & Thacker, 2006), there 
may have been an increase in transmission after arrival to the fattening herd.  
 
When pigs were vaccinated twice, on arrival and with a booster dose given 
28 days later, the vaccine failed to induce a protective immunity to A. 
pleuropneumoniae (Paper IV). Therefore, a three-dose vaccination protocol 
was commenced (on arrival and 28 and 56 days later). Also this vaccination 
scheme failed to protect pigs from developing clinical actinobacillosis. The 
purpose of the three-dose protocol was to prolong the period of protection 
induced by the vaccine as the protection is claimed to be of short duration 
(FASS vet., 2010).  
 
Another potential cause for the failure of the vaccine to induce a protective 
immunity in pigs receiving the first vaccination on arrival at the fattening 
herd may be that the pigs were vaccinated too late when they had already 
become infected. However, this was not believed to be the case, because 
pigs were generally seronegative on arrival and it has been demonstrated that 
a protective immunity can develop in pigs in spite of the presence of both 
passively derived and actively formed antibodies (Krejci et al., 2005). A 
three-dose vaccination protocol against actinobacillosis using the same 
vaccine as used in this vaccination trial also failed to prevent actinobacillosis 
although the first vaccination was performed at the age of six weeks 
according to the manufacturer’s instruction (Jirawattanapong et al., 2008). 
By vaccinating at the age of six weeks, piglets were allowed time to mount 
an immune response before they were likely to become infected. However, 
as piglets may become colonized already at 11 days of age, the vaccination 
time point may not be crucial for the development of a protective immunity 
(Vigre et al., 2002).  
 
It appears that the vaccine used failed to trigger the essential parts of the 
immune system in order to induce protective immunity. It appeared that the   50 
Apx toxins did not induce protective immunity when applied together with 
an OMP intra muscularly and that the presence of antibodies against LPS is 
indicative of protection if these antibodies are not protective in themselves. 
In this context, it could be argued that the antigen of the ELISA employed 
contained no protein and therefore only measured antibodies to LPS and 
CPS. As the vaccine used was based on the OMP and three toxoids (ApxI, 
ApxII and ApxIII), the ELISA did not detect antibodies induced by the 
vaccine itself. However, as clinical problems induced by A. pleuropneumoniae 
were continuously recorded in the herd, the vaccine failed to induce 
sufficient protection against A. pleuropneumoniae infections. At the first acute 
outbreak of actinobacillosis, a subsequent increase in antibody titers to A. 
pleuropneumoniae was detected with the LPS-based ELISA. This indicates the 
presence of the microbe in the herd which was confirmed as A. 
pleuropneumoniae serotype 2 was isolated at necropsy. 
 
The intra muscular application of the vaccine may not have induced local 
immunity which is considered likely to play an important role in the 
defence against A. pleuropneumoniae infections. Perhaps other routes for 
administration or other antigenic preparations could be more efficient. An 
intra dermal administration route which induces both mucosal and cell-
mediated immune responses has shown promising results (Bernardy et al., 
2008). Also, the use of live attenuated vaccines which mimic the natural 
course of an infection with A. pleuropneumoniae has a higher potential of 
conferring protective immunity against acute actinobacillosis (Maas et al., 
2006).  
 
Regardless, the pathogen load was reduced as registrations for pleuritis 
recorded at slaughter decreased from 25% to 5% over the two-year period 
when the study was performed although mortality rates and weight gains 
remained constant over time. It was striking that the incidence of pleuritis 
registered at slaughter decreased after terminating the vaccinations – both 
when pigs were vaccinated twice and when they were vaccinated three 
times. Thus, the vaccinations may have contributed to a decrease in the 
pathogen load of the herd, but the increased awareness among the staff for 
clinical signs of respiratory disease probably lead to an increased incidence of 
treatments that in turn certainly contributed significantly to the positive 
results. 
 
Weight gain is generally considered to reflect the health status of pigs well 
(Wallgren et al., 1993), and the influence of subclinical infections is immense   51 
(Wallgren, 2000). However, it may be difficult to demonstrate the effect of 
subclinical infections on growth in commercial herds (Andreasen et al., 
2001; Regula et al., 2000; Rohrbach et al., 1993; Hunneman, 1986). In 
accordance with this, no differences in growth rate between unvaccinated or 
vaccinated groups were recorded in the vaccination trial (Paper IV). 
 
Still, differences in DWG over time were observed in the herd considered 
to be endemically infected with A. pleuropneumoniae (Paper I). A reduction 
in weight gain was observed between the age of nine and 10 weeks which 
was followed by seroconversion at the age of 11 weeks. This reduction in 
weight gain most probably reflected the infection with A. pleuropneumoniae, 
but may also have been influenced by the “stress” imposed on the pigs as 
they were transferred to the weaning unit at this age. “Stress” is known to 
reduce growth rate (Rutherford et al., 2006; Sutherland et al., 2006; Hyun et 
al., 1998), but as “stress” also impairs immune functions (Salak-Johnson & 
McGlone, 2007), infections are more likely to affect pigs under “stress”. If 
pigs are subjected to “stress” at a time when passive immunity has subsided 
to low levels and they are not yet capable to mount a mature immune 
response to the particular pathogen, they would be even more prone to 
become infected and develop disease.  
 
Interestingly, there were some unexpected observations regarding the 
growth rate of the offspring to sows with low or high levels of serum 
antibodies to A. pleuropneumoniae (Paper I). Apart from the expected growth 
retardation seen at the time of seroconversion, reductions in weight gain 
were also observed on another two occasions further on during the rearing 
period. The reduction observed between the age of 12 and 13 weeks was 
believed to be due to crowding, as DWG increased after the transfer to 
larger pens in the same unit and there was no concurrent increase in serum 
antibodies indicating a re-exposure to A. pleuropneumoniae. Space allowance 
has previously been shown to affect weight gain (Brumm, 2004; Wolter et 
al., 2002). The increase in DWG observed after the transfer to the fattening 
unit despite the concurrent increase in serum antibodies to A. 
pleuropneumoniae  further  strengthens the assumption that crowding caused 
the reduced growth rates observed prior to the transfers. It also indicates that 
the pigs had developed a partial or complete resistance to the reinfection 
with A. pleuropneumoniae when they were transferred to the fattening unit 
with continuous production (Paper I). Also, the lymphocyte stimulations 
demonstrated that an exposure to A. pleuropneumoniae generated an   52 
activation of the humoral and cellular immune systems which implies that 
pigs can develop resistance to reinfections (Paper III). 
 
Although there was a difference in the serological responses to a natural 
infection with A. pleuropneumoniae in the offspring to sows with high or low 
levels of serum antibodies to A. pleuropneumoniae, this difference was not 
observed in the growth rate (Paper I). It has previously been demonstrated 
that pigs with a higher growth rate developed more severe clinical signs than 
pigs with moderate growth rate after a PRRS virus infection (Doeschl-
Wilson et al., 2009). In contrast, an increased growth rate has been reported 
among pigs consistently bred for high cellular and humoral immune 
responsiveness (Mallard et al., 1998). A large variation in the immune 
responsiveness between litters has been reported (Edfors-Lilja et al., 1994; 
Wallgren et al., 1994), and perhaps, a difference in weight gain could have 
been recorded if the piglets had been selected based on the capacity of their 
own immune system instead of the level of serum antibodies to A. 
pleuropneumoniae of their dams. 
 
On the other hand, acute infections with A. pleuropneumoniae definitely 
reduce growth (Wallgren et al., 1999b; Wallgren et al., 1999a) which was 
also confirmed in the experimental study (Papers II and III). Interestingly, 
there was also a reduction in DWG, even in the uninoculated pigs, 
following the first inoculation in the experimental trial (Paper II). This was 
believed to be caused by the frequent samplings (daily) performed during the 
first week after the inoculation as no clinical signs of respiratory disease were 
detected among the uninoculated pigs. As stated previously, “stress” has 
previously been shown to cause reductions in DWG (Hyun 1998, 
Rutherford 2006, Sutherland 2006). 
 
Considering theses findings, it can be concluded that systemic antibodies 
appear to mirror the protection against infections with A. pleuropneumoniae 
well (Papers I, II and III). Further, the level of circulating antibodies to A. 
pleuropneumoniae  in sows was concluded to be important for the level of 
protection transferred from sows to their offspring in colostrum (Paper I). 
Together, these findings suggest the possibility of increasing protection to A. 
pleuropneumoniae infections in both suckling piglets and growers. However, a 
similar protective immunity did not develop when fattening pigs were 
vaccinated against actinobacillosis using a commercially available vaccine 
(Paper IV). By studying the subsets of antibodies that are produced in 
response to infections with A. pleuropneumoniae, a more detailed picture of   53 
the protective humoral immunity could have been obtained. Even more 
clues on how antibodies play a role in the protection against A. 
pleuropneumoniae infections  could have been obtained if BALF had been 
analyzed.  
 
Other components than antibodies are also likely to be important in 
acquiring a protective immunity to infections with A. pleuropneumoniae. The 
acute-phase protein responses and the leukocyte counts observed in pigs 
inoculated with A. pleuropneumoniae indicated that pigs had mounted a 
protective immunity when re-exposed to the same strain (Papers II and III). 
Also the lymphocyte stimulations indicated that the immune system had 
been activated by an exposure to A. pleuropneumoniae (Paper III). 
Interestingly, the stimulatory index of lymphocytes, as well as the pMBL 
response, was higher following the second exposure to A. pleuropneumoniae, 
regardless if pigs had been previously challenged and mounted a subsequent 
immune response to the previous inoculation (Paper III). This may indicate 
that the immune system had matured from the first to the second 
inoculation,  i.e.  between the age of 10 to 14 weeks. This would be in 
agreement with clinical observations in farrow-to-finish herds with high 
pathogen loads that have improved health status and performance by 
increasing the age for the relocation of the pigs to the fattening unit from 
10-12 weeks of age to 14-16 weeks of age
3
  
. In agreement with this, an 
increased capacity of the immune system with age has been demonstrated in 
healthy piglets monitored from one to eight weeks of age (Grierson et al., 
2007). However, it should also be noted that no further improvement of the 
efficacy of the immune system was observed after ten weeks of age when 
pigs were followed until they were 15 weeks old (Juul-Madsen et al., 2010). 
Also other parts of the immune system, not included in these studies, may be 
equally important for the protection against A. pleuropneumoniae infections. 
Therefore further studies of the immune response to A. pleuropneumoniae 
infections are needed, not the least with the aim of developing vaccines 
which will mimic a natural infection with A. pleuropneumoniae well enough 
to induce partial or complete protectin against actinobacillosis.  
 
                                                  
3 Wallgren, unpublished data   54 
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 #ONCLUSIONSÖ
 Serum antibodies to polysaccharides of A. pleuropneumoniae appear to play 
an important role in the protection against A. pleuropneumoniae infections. 
 There are indications that protection against infections with A. 
pleuropneumoniae  may be enhanced in piglets by improving serum 
antibody levels of sows. This could possibly be achieved by vaccinations 
of sows, as levels of serum antibodies to A. pleuropneumoniae in sows are 
reflected in colostral levels. Sows with high levels of serum antibodies 
show high levels of colostral antibodies. 
 Offspring to sows with high levels of antibodies to A. pleuropneumoniae 
had higher levels of serum antibodies that persisted for a longer period of 
time compared to piglets from sows with lower levels of antibodies. 
Thus, these piglets are more likely to be better protected against 
infections with A. pleuropneumoniae. 
 Offspring to sows with high levels of antibodies to A. pleuropneumoniae 
produced higher concentrations of antibodies to A. pleuropneumoniae 
when they seroconverted. By vaccinating piglets, immunity on herd level 
could be enhanced with fewer piglets being susceptible to disease when 
they encounter the pathogen. This is likely to occur following the 
transfer to a fattening unit. 
 When treating clinical cases of actinobacillosis, attention should be paid 
to the severity of disease symptoms, the number of affected animals and if 
pigs are likely to re-encounter infections with A.  pleuropneumoniae 
when selecting the drug for treatment. Treatment with enrofloxacin may 
be required for pigs with severe clinical symptoms as they are otherwise 
likely to die. However, if pigs risk to be reinfected at a later point during 
the rearing period, tetracycline may be the drug of choice. Another 
advantage with tetracycline is that it can be used for group-medication 
should many pigs be affected. Penicillin treatments of infections with A. 
pleuropneumoniae are questionable using the recommended doses and dose 
intervals. 
 Vaccinations against actinobacillosis may reduce the pathogen load over 
time as indicated by a reduced incidence of pleuritits recorded at 
slaughter in a specialized fattening herd. However, the vaccine 
commercially available today did not induce protective immunity in 
itself. Various preventive measures and medical treatments are therefore 
still of importance to prevent clinical disease and to reduce the incidence 
of pleuritis recorded at slaughter. 
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 )MPLICATIONSÖFORÖFUTUREÖRESEARCHÖÖ
 Identify key virulence factors for Actinobacillus pleuropneumoniae in 
order to be able to develop vaccines conferring protection against 
infections with A. pleuropneumoniae. 
 
 Investigate how different routes of vaccine administration influence 
the development of systemic and local immunity so that vaccines 
inducing appropriate local and systemic protective immunity can be 
developed. 
 
 Investigate the possibility of vaccinating sows in order to obtain a 
higher level of protection for the piglets under a longer period of time 
which may also reduce the number of subclinical carriers. 
 
 Investigate in more detail immunological parameters in offspring to 
sows with high and low amounts of antibodies to A. pleuropneumoniae. 
 
 Extend the studies on the long-term effects of treatment strategies by 
investigating if and how the time point for initiating enrofloxacin 
treatments of A. pleuropneumoniae infections will influence the 
development of disease and the immune response.    58 
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 0OPUL¦RVETENSKAPLIGÖSAMMANFATTNINGÖ
 "AKGRUNDÖ
Actinobacillus pleuropneumoniae är en bakterie som kan ge upphov till allvarliga 
lunginfektioner hos grisar. Den allvarligaste formen, så kallad elakartad 
lungsjuka, förlöper ofta med dödlig utgång. Grisar som insjuknar i elakartad 
lungsjuka upphör att äta, får hög feber, hosta och andnöd men kan även dö 
utan föregående symtom. Vanligare är dock en kronisk form där sjukdomen 
inte ger några märkbara tecken på sjukdom utan ofta upptäcks som mer eller 
mindre utbredda brösthinneinflammationer i samband med besiktningen vid 
slakt. 
 
Sedan 1986, då rutinmässig användning av så kallade tillväxtbefrämjande 
tillsatser av antibiotika i fodret till livsmedelsproducerande djur förbjöds, har 
aktiva insatser utvecklats för att minska sjukligheten vilket har bidragit till det 
gynnsamma hälsoläge som råder inom svensk grisproduktion. Bland annat 
infördes omgångsproduktion från födsel till slakt i större omfattning. 
Omgångsproduktion innebär att avkommorna till en grupp suggor som 
grisar in under cirka en veckas tid föds upp tillsammans utan att blandas med 
grisar av annan ålder. Denna åtgärd bidrog till att spridningen av 
luftvägsinfektioner minskade under 1990-talet. 
 
Under senare år har dock trenden vänt och ett ökat antal registreringar av 
brösthinneinflammationer och fler akuta utbrott av elakartad lungsjuka har 
rapporterats. Bidragande orsaker till detta kan vara att besättningsstorleken 
ökat. Detta innebär att antalet mottagliga djur och antalet möjliga smittvägar 
ökar per besättning, liksom att konsekvenserna av ett sjukdomsutbrott blir 
större.   60 
Därför har åtgärder vidtagits, såväl för att förhindra uppkomsten av problem 
som för att minska skadornas omfattning när infektionen har brutit ut. I ett 
akut skede används antibiotika för att behandla sjuka grisar. 
Individbehandlingar då grisarna sprutas med lämpligt antibiotikum används 
framför allt om enstaka grisar eller boxar har insjuknat. Har större delar av en 
omgång eller till och med en hel besättning drabbats medicineras grisarna 
vanligen i foder eller vatten.  
 
All antibiotikaanvändning medför dock en risk för att resistens skall 
utvecklas. I Sverige förekommer idag ingen känd resistens mot de 
antibiotika som används för att behandla infektioner med A. 
pleuropneumoniae. Däremot har resistensutveckling blivit vanligare i andra 
länder. 
 
Därför är det angeläget att förebygga uppkomsten av sjukdom. Förutom 
omgångsuppfödning har även ventilation, tvätt- och desinfektion mellan 
omgångar samt vaccination använts för att förebygga uppkomsten av 
sjukdom orsakad av A. pleuropneumoniae. Tyvärr har vaccination hittills inte 
visat sig vara särskilt effektivt för att minska uppkomsten av sjukdom. 
Däremot är grisar som har genomgått en infektion och överlevt skyddade 
mot återinfektioner. Därför var syftet med de undersökningar som utfördes 
inom ramen för detta avhandlingsarbete att öka kunskapen om hur 
immunförsvaret påverkas av infektionen och hur detta kan ha betydelse för 
grisens skydd mot nya infektioner. 
 3AMMANFATTNINGÖAVÖSTUDIERÖOCHÖRESULTATÖ
I den första studien som genomfördes i en konventionell, integrerad 
besättning undersöktes betydelsen av suggans immunitet för avkommornas 
skydd mot en infektion med A. pleuropneumoniae under uppväxten. Det 
visade sig att mängden antikroppar i blodet hos suggan även avspeglade sig i 
den mängd antikroppar som suggorna förde över till smågrisarna via 
råmjölken. Suggor som hade högre antikroppsnivåer i blodet hade även en 
större mängd antikroppar i råmjölken som dessutom avspeglade sig i den 
mängd antikroppar som kunde påvisas i smågrisarnas blod. Antikroppar 
kunde även påvisas under längre tid hos de smågrisar som hade fått en större 
mängd antikroppar via råmjölken. Detta tyder på att dessa smågrisar skulle 
kunna vara bättre skyddade mot en infektion med A. pleuropneumoniae. Dessa 
smågrisar bildade dessutom en större mängd antikroppar när de blev 
infekterade med A. pleuropneumoniae senare under uppfödningen.   61 
Tidpunkten för infektionen återspeglade sig även i tillväxten som sjönk då. 
Däremot utvecklade inga av grisarna några allvarliga tecken på 
luftvägssjukdom vilket antyder att de utvecklade ett eget skydd mot 
infektionen. 
 
I den andra studien undersöktes hur immunitetsutvecklingen påverkades av 
behandling med olika antibiotika efter en infektion med A. pleuropneumoniae. 
Grisarna infekterades återigen 28 dagar efter den första infektionen med 
samma stam av A. pleuropneumoniae. Denna gång utfördes inga behandlingar. 
Det visade sig att de grisar som behandlats med enrofloxacin tillfrisknade 
mycket snart efter behandling. De utvecklade ett akutfasproteinsvar men 
bildade inga antikroppar. När de senare utsattes för samma smitta på nytt 
utan samtidig behandling blev de lika sjuka som de grisar som infekterades 
utan att behandlas. De enrofloxacinbehandlade grisarna uppvisade återigen 
ett akutfasproteinsvar efter den andra infektionen. Detta svar var i paritet 
med det som sågs hos den grupp grisar som tidigare inte infekterats och som 
nu mötte infektionen för första gången. Djuren i båda dessa grupper bildade 
även antikroppar mot A. pleuropneumoniae denna gång. 
 
De grisar som behandlades med tetracyklin svarade i princip lika bra kliniskt 
på behandling som de enrofloxacinbehandlade grisarna men till skillnad från 
dessa så påverkades de inte vid återinfektionen vilket även avspeglade sig i ett 
uteblivet akutfasproteinsvar efter återinfektionen. De penicillinbehandlade 
grisarna svarade däremot inte särskilt bra på behandling kliniskt sett utan blev 
lika sjuka som de grisar som infekterades utan att behandlas. Efter den första 
infektionen utvecklade dessa grisar såväl ett akutfasproteinsvar som 
antikroppar mot A. pleuropneumoniae. Därmed hade de utvecklat en 
skyddande immunitet vid tidpunkten för återinfektionen. 
 
I den tredje studien undersöktes effekten av ett kommersiellt tillgängligt 
vaccin mot infektioner med A. pleuropneumoniae i en slaktsvinsbesättning 
som haft problem med anmärkningar för brösthinneinflammationer vid slakt 
och som också drabbats av ett akut utbrott av elakartad lungsjuka. Grisarna 
vaccinerades med ett kommersiellt tillgängligt vaccin vid ankomst till 
besättningen samt fyra veckor senare i ett första skede. Senare vaccinerades 
grisarna tre gånger med den första vaccinationen vid ankomst och de 
efterföljande två vaccinationerna med fyra veckors mellanrum. Tyvärr 
minskade inte förekomsten av elakartad lungsjuka hos de vaccinerade 
grisarna. Däremot sjönk antalet registrerade brösthinneinflammationer vid 
slakt markant med tiden. Studien visade att vaccinationerna inte skyddade   62 
grisarna mot sjukdom men att smittrycket minskade över tid. Huruvida detta 
var en effekt av vaccinationerna kan inte säkert visas. Troligen kan en ökad 
uppmärksamhet bland personalen ha bidragit till att fler fall av akuta 
lunginflammationer upptäcktes med en ökad behandlingsfrekvens som följd. 
Sannolikt har den ökade frekvensen behandlingar bidragit till att minska 
smittrycket vilket visade sig i färre registrerade brösthinneinflammationer vid 
slakt. 
 
Sammanfattningsvis kan sägas att förekomsten av antikroppar riktade mot A. 
pleuropneumoniae avspeglar immunitet mot sjukdom väl. Detta öppnar för 
möjligheten att öka skyddet hos både diande och växande grisar genom att 
höja nivåerna av cirkulerande antikroppar hos suggorna och därmed öka 
mängden antikroppar i råmjölken. Detta måste dock göras på ett kontrollerat 
sätt, exempelvis genom vaccination av suggor och förutsätter att 
vaccinationen leder till en antikroppsstegring och att dessa antikroppar blir 
skyddande. Framtagande av väl fungerande vacciner till växande grisar kan 
också utgöra ett alternativ för att kontrollera infektionen, dock måste 
vacciner som ger upphov till en skyddande immunitet utvecklas först.   63 
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